******* QUERY RESULTS *******
(COMPOUNDS FROM CLAIMS 28-51)

```
=> d his l45

     (FILE 'STNGUIDE' ENTERED AT 08:27:22 ON 10 MAR 2009)

     FILE 'REGISTRY' ENTERED AT 08:28:18 ON 10 MAR 2009
L45         209 S L3 OR L5 OR L7 OR L10 OR L14 OR L16 OR L21 OR L23 OR L25 OR L

=> d que l45
L1           12 SEA FILE=REGISTRY ABB=ON  PLU=ON  (676633-01-5/RN OR 676633-02-
                6/RN OR 676633-03-7/RN OR 676633-04-8/RN OR 676633-05-9/RN OR
                676633-06-0/RN OR 676633-07-1/RN OR 676633-08-2/RN OR 676633-09
                -3/RN OR 676633-10-6/RN OR 676633-11-7/RN OR 676633-12-8/RN)
L3            5 SEA FILE=REGISTRY ABB=ON  PLU=ON  L1 AND "L()VALINAMIDE"
L4           22 SEA FILE=REGISTRY ABB=ON  PLU=ON  (676633-13-9/RN OR 676633-14-
                0/RN OR 676633-15-1/RN OR 676633-16-2/RN OR 676633-17-3/RN OR
                676633-18-4/RN OR 676633-19-5/RN OR 676633-20-8/RN OR 676633-21
                -9/RN OR 676633-22-0/RN OR 676633-23-1/RN OR 676633-24-2/RN OR
                676633-25-3/RN OR 676633-26-4/RN OR 676633-27-5/RN OR 676633-28
                -6/RN OR 676633-29-7/RN OR 676633-30-0/RN OR 676633-31-1/RN OR
                676633-32-2/RN OR 676633-33-3/RN OR 676633-34-4/RN)
L5           11 SEA FILE=REGISTRY ABB=ON  PLU=ON  L4 AND "L()VALINAMIDE"
L6           22 SEA FILE=REGISTRY ABB=ON  PLU=ON  (676633-39-9/RN OR 676633-40-
                2/RN OR 676633-41-3/RN OR 676633-42-4/RN OR 676633-43-5/RN OR
                676633-44-6/RN OR 676633-45-7/RN OR 676633-46-8/RN OR 676633-47
                -9/RN OR 676633-48-0/RN OR 676633-49-1/RN OR 676633-50-4/RN OR
                676633-51-5/RN OR 676633-52-6/RN OR 676633-53-7/RN OR 676633-54
                -8/RN OR 676633-55-9/RN OR 676633-56-0/RN OR 676633-57-1/RN OR
                676633-58-2/RN OR 676633-59-3/RN OR 676633-60-6/RN)
L7           13 SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 AND "L()VALINAMIDE"
L9           20 SEA FILE=REGISTRY ABB=ON  PLU=ON  (676633-61-7/RN OR 676633-62-
                8/RN OR 676633-63-9/RN OR 676633-64-0/RN OR 676633-65-1/RN OR
                676633-66-2/RN OR 676633-67-3/RN OR 676633-68-4/RN OR 676633-69
                -5/RN OR 676633-70-8/RN OR 676633-71-9/RN OR 676633-72-0/RN OR
                676633-73-1/RN OR 676633-74-2/RN OR 676633-75-3/RN OR 676633-76
                -4/RN OR 676633-77-5/RN OR 676633-78-6/RN OR 676633-79-7/RN OR
                676633-80-0/RN)
L10           8 SEA FILE=REGISTRY ABB=ON  PLU=ON  L9 AND "L()VALINAMIDE"
L13          46 SEA FILE=REGISTRY ABB=ON  PLU=ON  (676633-83-3/RN OR 676633-84-
                4/RN OR 676633-85-5/RN OR 676633-86-6/RN OR 676633-87-7/RN OR
                676633-88-8/RN OR 676633-89-9/RN OR 676633-90-2/RN OR 676633-91
                -3/RN OR 676633-92-4/RN OR 676633-93-5/RN OR 676633-94-6/RN OR
                676633-95-7/RN OR 676633-96-8/RN OR 676633-97-9/RN OR 676633-98
                -0/RN OR 676633-99-1/RN OR 676634-00-7/RN OR 676634-01-8/RN OR
                676634-02-9/RN OR 676634-03-0/RN OR 676634-04-1/RN OR 676634-05
                -2/RN OR 676634-06-3/RN OR 676634-07-4/RN OR 676634-08-5/RN OR
                676634-09-6/RN OR 676634-10-9/RN OR 676634-11-0/RN OR 676634-12
                -1/RN OR 676634-13-2/RN OR 676634-14-3/RN OR 676634-15-4/RN OR
                676634-16-5/RN OR 676634-17-6/RN OR 676634-18-7/RN OR 676634-19
                -8/RN OR 676634-20-1/RN OR 676634-21-2/RN OR 676634-22-3/RN OR
                676634-23-4/RN OR 676634-24-5/RN OR 676634-25-6/RN OR 676634-26
                -7/RN OR 676634-27-8/RN OR 676634-28-9/RN)
L14          13 SEA FILE=REGISTRY ABB=ON  PLU=ON  L13 AND "L()VALINAMIDE"
L15          45 SEA FILE=REGISTRY ABB=ON  PLU=ON  (676634-31-4/RN OR 676634-32-
                5/RN OR 676634-33-6/RN OR 676634-34-7/RN OR 676634-35-8/RN OR
                676634-36-9/RN OR 676634-37-0/RN OR 676634-38-1/RN OR 676634-39
                -2/RN OR 676634-40-5/RN OR 676634-41-6/RN OR 676634-42-7/RN OR
                676634-43-8/RN OR 676634-44-9/RN OR 676634-45-0/RN OR 676634-46
```

-1/RN OR 676634-47-2/RN OR 676634-48-3/RN OR 676634-49-4/RN OR 676634-50-7/RN OR 676634-51-8/RN OR 676634-52-9/RN OR 676634-53-0/RN OR 676634-54-1/RN OR 676634-55-2/RN OR 676634-56-3/RN OR 676634-57-4/RN OR 676634-58-5/RN OR 676634-59-6/RN OR 676634-60-9/RN OR 676634-61-0/RN OR 676634-62-1/RN OR 676634-63-2/RN OR 676634-64-3/RN OR 676634-65-4/RN OR 676634-66-5/RN OR 676634-67-6/RN OR 676634-68-7/RN OR 676634-69-8/RN OR 676634-70-1/RN OR 676634-71-2/RN OR 676634-72-3/RN OR 676634-73-4/RN OR 676634-74-5/RN OR 676634-75-6/RN)

L16 14 SEA FILE=REGISTRY ABB=ON PLU=ON L15 AND "L()VALINAMIDE"

L20 58 SEA FILE=REGISTRY ABB=ON PLU=ON (676634-77-8/RN OR 676634-78-9/RN OR 676634-79-0/RN OR 676634-80-3/RN OR 676634-81-4/RN OR 676634-82-5/RN OR 676634-83-6/RN OR 676634-84-7/RN OR 676634-85-8/RN OR 676634-86-9/RN OR 676634-87-0/RN OR 676634-88-1/RN OR 676634-89-2/RN OR 676634-90-5/RN OR 676634-91-6/RN OR 676634-92-7/RN OR 676634-93-8/RN OR 676634-94-9/RN OR 676634-95-0/RN OR 676634-96-1/RN OR 676634-97-2/RN OR 676634-98-3/RN OR 676634-99-4/RN OR 676635-00-0/RN OR 676635-01-1/RN OR 676635-02-2/RN OR 676635-03-3/RN OR 676635-04-4/RN OR 676635-05-5/RN OR 676635-06-6/RN OR 676635-07-7/RN OR 676635-08-8/RN OR 676635-09-9/RN OR 676635-10-2/RN OR 676635-11-3/RN OR 676635-12-4/RN OR 676635-13-5/RN OR 676635-14-6/RN OR 676635-15-7/RN OR 676635-16-8/RN OR 676635-17-9/RN OR 676635-18-0/RN OR 676635-19-1/RN OR 676635-20-4/RN OR 676635-21-5/RN OR 676635-22-6/RN OR 676635-23-7/RN OR 676635-24-8/RN OR 676635-25-9/RN OR 676635-26-0/RN OR 676635-27-1/RN OR 676635-28-2/RN OR 676635-29-3/RN OR 676635-30-6/RN OR 676635-31-7/RN OR 676635-32-8/RN OR 676635-33-9/RN OR 676635-34-0/RN)

L21 25 SEA FILE=REGISTRY ABB=ON PLU=ON L20 AND "L()VALINAMIDE"

L22 67 SEA FILE=REGISTRY ABB=ON PLU=ON (676635-33-9/RN OR 676635-34-0/RN OR 676635-35-1/RN OR 676635-36-2/RN OR 676635-37-3/RN OR 676635-38-4/RN OR 676635-39-5/RN OR 676635-40-8/RN OR 676635-41-9/RN OR 676635-42-0/RN OR 676635-43-1/RN OR 676635-44-2/RN OR 676635-45-3/RN OR 676635-46-4/RN OR 676635-47-5/RN OR 676635-48-6/RN OR 676635-49-7/RN OR 676635-50-0/RN OR 676635-51-1/RN OR 676635-52-2/RN OR 676635-53-3/RN OR 676635-54-4/RN OR 676635-55-5/RN OR 676635-56-6/RN OR 676635-57-7/RN OR 676635-58-8/RN OR 676635-59-9/RN OR 676635-60-2/RN OR 676635-61-3/RN OR 676635-62-4/RN OR 676635-63-5/RN OR 676635-64-6/RN OR 676635-65-7/RN OR 676635-66-8/RN OR 676635-67-9/RN OR 676635-68-0/RN OR 676635-69-1/RN OR 676635-70-4/RN OR 676635-71-5/RN OR 676635-72-6/RN OR 676635-73-7/RN OR 676635-74-8/RN OR 676635-75-9/RN OR 676635-76-0/RN OR 676635-77-1/RN OR 676635-78-2/RN OR 676635-79-3/RN OR 676635-80-6/RN OR 676635-81-7/RN OR 676635-82-8/RN OR 676635-83-9/RN OR 676635-84-0/RN OR 676635-85-1/RN OR 676635-86-2/RN OR 676635-87-3/RN OR 676635-88-4/RN OR 676635-89-5/RN OR 676635-90-8/RN OR 676635-91-9/RN OR 676635-92-0/RN OR 676635-93-1/RN OR 676635-94-2/RN OR 676635-95-3/RN OR 676635-96-4/RN OR 676635-97-5/RN OR 676635-98-6/RN OR 676635-99-7/RN)

L23 21 SEA FILE=REGISTRY ABB=ON PLU=ON L22 AND "L()VALINAMIDE"

L25 1 SEA FILE=REGISTRY ABB=ON PLU=ON L22 AND LEUCINAMIDE

L27 27 SEA FILE=REGISTRY ABB=ON PLU=ON (676636-02-5/RN OR 676636-03-6/RN OR 676636-04-7/RN OR 676636-05-8/RN OR 676636-06-9/RN OR 676636-07-0/RN OR 676636-08-1/RN OR 676636-09-2/RN OR 676636-10-5/RN OR 676636-11-6/RN OR 676636-12-7/RN OR 676636-13-8/RN OR 676636-14-9/RN OR 676636-15-0/RN OR 676636-16-1/RN OR 676636-17-2/RN OR 676636-18-3/RN OR 676636-19-4/RN OR 676636-20-7/RN OR 676636-21-8/RN OR 676636-22-9/RN OR 676636-23-0/RN OR 676636-24-1/RN OR 676636-25-2/RN OR 676636-26-3/RN OR 676636-27-4/RN OR 676636-28-5/RN)

L28 14 SEA FILE=REGISTRY ABB=ON PLU=ON L27 AND "L()VALINAMIDE"
L29 22 SEA FILE=REGISTRY ABB=ON PLU=ON (676636-77-4/RN OR 676636-78-5/RN OR 676636-79-6/RN OR 676636-80-9/RN OR 676636-81-0/RN OR 676636-82-1/RN OR 676636-83-2/RN OR 676636-84-3/RN OR 676636-85-4/RN OR 676636-86-5/RN OR 676636-87-6/RN OR 676636-88-7/RN OR 676636-89-8/RN OR 676636-90-1/RN OR 676636-91-2/RN OR 676636-92-3/RN OR 676636-93-4/RN OR 676636-94-5/RN OR 676636-95-6/RN OR 676636-96-7/RN OR 676636-97-8/RN OR 676636-98-9/RN)
L30 4 SEA FILE=REGISTRY ABB=ON PLU=ON L29 AND "L()VALINAMIDE"
L31 29 SEA FILE=REGISTRY ABB=ON PLU=ON (676637-00-6/RN OR 676637-01-7/RN OR 676637-02-8/RN OR 676637-03-9/RN OR 676637-04-0/RN OR 676637-05-1/RN OR 676637-06-2/RN OR 676637-07-3/RN OR 676637-08-4/RN OR 676637-09-5/RN OR 676637-10-8/RN OR 676637-11-9/RN OR 676637-12-0/RN OR 676637-13-1/RN OR 676637-14-2/RN OR 676637-15-3/RN OR 676637-16-4/RN OR 676637-17-5/RN OR 676637-18-6/RN OR 676637-19-7/RN OR 676637-20-0/RN OR 676637-21-1/RN OR 676637-22-2/RN OR 676637-23-3/RN OR 676637-24-4/RN OR 676637-25-5/RN OR 676637-26-6/RN OR 676637-27-7/RN OR 676637-28-8/RN)
L32 8 SEA FILE=REGISTRY ABB=ON PLU=ON L31 AND "L()VALINAMIDE"
L33 70 SEA FILE=REGISTRY ABB=ON PLU=ON (676631-37-1/RN OR 676631-38-2/RN OR 676631-39-3/RN OR 676631-40-6/RN OR 676631-41-7/RN OR 676631-42-8/RN OR 676631-43-9/RN OR 676631-44-0/RN OR 676631-45-1/RN OR 676631-46-2/RN OR 676631-47-3/RN OR 676631-48-4/RN OR 676631-49-5/RN OR 676631-50-8/RN OR 676631-51-9/RN OR 676631-52-0/RN OR 676631-53-1/RN OR 676631-54-2/RN OR 676631-55-3/RN OR 676631-56-4/RN OR 676631-57-5/RN OR 676631-58-6/RN OR 676631-59-7/RN OR 676631-60-0/RN OR 676631-61-1/RN OR 676631-62-2/RN OR 676631-63-3/RN OR 676631-64-4/RN OR 676631-65-5/RN OR 676631-66-6/RN OR 676631-67-7/RN OR 676631-68-8/RN OR 676631-69-9/RN OR 676631-70-2/RN OR 676631-71-3/RN OR 676631-72-4/RN OR 676631-73-5/RN OR 676631-74-6/RN OR 676631-75-7/RN OR 676631-76-8/RN OR 676631-77-9/RN OR 676631-78-0/RN OR 676631-79-1/RN OR 676631-80-4/RN OR 676631-81-5/RN OR 676631-82-6/RN OR 676631-83-7/RN OR 676631-84-8/RN OR 676631-85-9/RN OR 676631-86-0/RN OR 676631-87-1/RN OR 676631-88-2/RN OR 676631-89-3/RN OR 676631-90-6/RN OR 676631-91-7/RN OR 676631-92-8/RN OR 676631-93-9/RN OR 676631-94-0/RN OR 676631-95-1/RN OR 676631-96-2/RN OR 676631-97-3/RN OR 676631-98-4/RN OR 676631-99-5/RN OR 676632-00-1/RN OR 676632-01-2/RN OR 676632-02-3/RN OR 676632-03-4/RN OR 676632-04-5/RN OR 676632-05-6/RN OR 676632-06-7/RN)
L34 30 SEA FILE=REGISTRY ABB=ON PLU=ON L33 AND "L()VALINAMIDE"
L35 108 SEA FILE=REGISTRY ABB=ON PLU=ON (676632-05-6/RN OR 676632-06-7/RN OR 676632-07-8/RN OR 676632-08-9/RN OR 676632-09-0/RN OR 676632-10-3/RN OR 676632-11-4/RN OR 676632-12-5/RN OR 676632-13-6/RN OR 676632-14-7/RN OR 676632-15-8/RN OR 676632-16-9/RN OR 676632-17-0/RN OR 676632-18-1/RN OR 676632-19-2/RN OR 676632-20-5/RN OR 676632-21-6/RN OR 676632-22-7/RN OR 676632-23-8/RN OR 676632-24-9/RN OR 676632-25-0/RN OR 676632-26-1/RN OR 676632-27-2/RN OR 676632-28-3/RN OR 676632-29-4/RN OR 676632-30-7/RN OR 676632-31-8/RN OR 676632-32-9/RN OR 676632-33-0/RN OR 676632-34-1/RN OR 676632-35-2/RN OR 676632-36-3/RN OR 676632-37-4/RN OR 676632-38-5/RN OR 676632-39-6/RN OR 676632-40-9/RN OR 676632-41-0/RN OR 676632-42-1/RN OR 676632-43-2/RN OR 676632-44-3/RN OR 676632-45-4/RN OR 676632-46-5/RN OR 676632-47-6/RN OR 676632-48-7/RN OR 676632-49-8/RN OR 676632-50-1/RN OR 676632-51-2/RN OR 676632-52-3/RN OR 676632-53-4/RN OR 676632-54-5/RN OR 676632-55-6/RN OR 676632-56-7/RN OR 676632-57-8/RN OR 676632-58-9/RN OR 676632-59-0/RN OR 676632-60-3/RN OR 676632-61-4/RN OR 676632-62-5/RN OR 676632-63-6/RN OR 676632-64-7/RN OR 676632-65-8/RN OR 676632-66-9/RN OR 676632-67-0/RN OR 676632-68-1/RN OR 676632-69

-2/RN OR 676632-70-5/RN OR 676632-71-6/RN OR 676632-72-7/RN OR 676632-73-8/RN OR 676632-74-9/RN OR 676632-75-0/RN OR 676632-76-1/RN OR 676632-77-2/RN OR 676632-78-3/RN OR 676632-79-4/RN OR 676632-80-7/RN OR 676632-81-8/RN OR 676632-82-9/RN OR 676632-83-0/RN OR 676632-84-1/RN OR 676632-85-2/RN OR 676632-86-3/RN OR 676632-87-4/RN OR 676632-88-5/RN OR 676632-89-6/RN OR 676632-90-9/RN OR 676632-91-0/RN OR 676632-92-1/RN OR 676632-93-2/RN OR 676632-94-3/RN OR 676632-95-4/RN OR 676632-96-5/RN OR 676632-97-6/RN OR 676632-98-7/RN OR 676632-99-8/RN OR 676633-00-4/RN OR 676633-01-5/RN OR 676633-02-6/RN OR 676633-03-7/RN OR 676633-04-8/RN OR 676633-05-9/RN OR 676633-06-0/RN OR 676633-07-1/RN OR 676633-08-2/RN OR 676633-09-3/RN OR 676633-10-6/RN OR 676633-11-7/RN OR 676633-12-8/RN)

L36 48 SEA FILE=REGISTRY ABB=ON PLU=ON L35 AND "L()VALINAMIDE"

L45 209 SEA FILE=REGISTRY ABB=ON PLU=ON L3 OR L5 OR L7 OR L10 OR L14 OR L16 OR L21 OR L23 OR L25 OR L28 OR L30 OR L32 OR L34 OR L36

=> d l45 1-209 ide

L45 ANSWER 1 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676637-28-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(2-methylpropyl)-2-pentenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H47 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 2 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676637-26-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S)-1-[(1E)-2-carboxy-1-propenyl]pentyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

FS STEREOSEARCH
MF C28 H45 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 3 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676637-15-3 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,3-dimethyl-4-phenylvalyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H49 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 4 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676637-13-1 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,4-bis[(1,1-dimethylethoxy)carbonyl]-N,β,β-trimethylphenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C39 H63 N3 O8
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 5 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676637-11-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,3-tetramethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676631-84-8
CMF C28 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 6 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676637-09-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,3-tetramethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676631-81-5
CMF C28 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 7 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676637-03-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 2-methoxy-N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H51 N3 O6
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 8 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676637-00-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H49 N3 O5
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 9 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676636-97-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 2-methoxy-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H49 N3 O5
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 10 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676636-82-1 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-[[(4-methoxyphenyl)methyl]thio]-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C34 H49 N3 O5 S
CI COM
SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 11 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676636-79-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl-3-(methylthio)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H43 N3 O4 S
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, SYNTHLINE, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 12 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676636-77-4 REGISTRY

ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N-methyl-3-(methylthio)-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H47 N3 O4 S
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 13 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676636-28-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1R,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H43 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676636-27-4
CMF C27 H43 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 14 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676636-27-4 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1R,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H43 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 15 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676636-25-2 REGISTRY

ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-hydroxy-N-methyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H41 N3 O5 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676636-24-1
CMF C26 H41 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 16 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676636-24-1 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-hydroxy-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H41 N3 O5
CI COM

SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 17 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676636-22-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-acetyl-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H45 N3 O5 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676636-21-8
CMF C29 H45 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 18 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676636-21-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-acetyl-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H45 N3 O5
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 19 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676636-19-4 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, {βR}-N,β-dimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H41 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

CM 1

CRN 676636-18-3
CMF C26 H41 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 20 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676636-18-3 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, (βR)-N,β-dimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H41 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 21 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676636-15-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N-(2-hydroxyethyl)-β,β-dimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O5 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

CM 1

CRN 676636-14-9
CMF C28 H45 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 22 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676636-14-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N-(2-hydroxyethyl)-β,β-dimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O5
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 23 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676636-07-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N-ethyl-β,β-dimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

CM 1

CRN 676636-06-9
CMF C28 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 24 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676636-06-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N-ethyl-β,β-dimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 25 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676636-03-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-[[(4-methoxyphenyl)methyl]thio]-N-methyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H47 N3 O5 S . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676636-02-5
CMF C29 H47 N3 O5 S

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 26 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676636-02-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-[[(4-methoxyphenyl)methyl]thio]-N-methyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H47 N3 O5 S
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 27 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-99-7 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-fluoro-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H40 F N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676635-98-6
CMF C26 H40 F N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 28 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-98-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-fluoro-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H40 F N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 29 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-88-4 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-4-[(1E)-2-phenylethenyl]-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H49 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676635-87-3
CMF C35 H49 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 30 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-87-3 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-4-[(1E)-2-phenylethenyl]-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H49 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 31 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-84-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-4-[(1E)-2-phenylethenyl]-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H49 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

CM 1

CRN 676635-83-9
CMF C35 H49 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 32 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-83-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-4-[(1E)-2-phenylethenyl]-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H49 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 33 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-72-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, (2R)-N-methyl-2-(1-phenylcyclopropyl)glycyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H41 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676635-71-5
CMF C27 H41 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 34 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-71-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, (2R)-N-methyl-2-(1-phenylcyclopropyl)glycyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H41 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 35 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-68-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, (2S)-N-methyl-2-(1-phenylcyclopropyl)glycyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H41 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 36 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-62-4 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, L-leucyl-N-[(1R,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H37 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 37 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-58-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(phenylmethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H43 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 38 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-56-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-D-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H47 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 39 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-50-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-(1-naphthalenyl)-L-alanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)
FS STEREOSEARCH

MF C28 H39 N3 O4 . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (676637-75-5)

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 40 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-47-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N-methyl-O-(phenylmethyl)-L-threonyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H43 N3 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 41 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-45-3 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, {βS)-N,β-dimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H41 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 42 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-43-1 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, β,β-diethyl-N-methyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H47 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 43 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-41-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, β,β-diethyl-N-methyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H47 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 44 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-39-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1R,3R)-3-carboxy-1-(1-methylethyl)butyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H45 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

CM 1

CRN 676635-38-4
CMF C27 H45 N3 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 45 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-38-4 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1R,3R)-3-carboxy-1-(1-methylethyl)butyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H45 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 46 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-36-2 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1R,3S)-3-carboxy-1-(1-methylethyl)butyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H45 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

CM 1

CRN 676635-35-1
CMF C27 H45 N3 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 47 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-35-1 REGISTRY

ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1R,3S)-3-carboxy-1-(1-methylethyl)butyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H45 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 48 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-33-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Isoleucinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676635-32-8
CMF C28 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 49 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-31-7 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 4,5-didehydro-N,3-dimethylisoleucyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H41 N3 O4 . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (676637-78-8)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 50 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-24-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(2-propenyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H41 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676635-23-7
CMF C27 H41 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 51 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-23-7 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(2-propenyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH

MF C27 H41 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 52 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-21-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-propenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H41 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676635-20-4
CMF C26 H41 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 53 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-20-4 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-propenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H41 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 54 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-17-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2Z)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H43 N3 O4 . C2 H F3 O2

SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676635-16-8
CMF C27 H43 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 55 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-16-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2Z)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H43 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 56 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-14-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N,3-dimethyl-N-[(1S,2E)-3-methyl-1-(1-methylethyl)-4-(octyloxy)-4-oxo-2-butenyl]-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H59 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 57 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-12-4 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N,3-dimethyl-N-[(1S,2E)-3-methyl-1-(1-methylethyl)-4-oxo-4-(2-thienylmethoxy)-2-butenyl]-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H47 N3 O4 S

CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 58 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-09-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-[[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]methylamino]-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C36 H58 N4 O5 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676635-08-8
CMF C36 H58 N4 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 59 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-08-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-[[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]methylamino]-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C36 H58 N4 O5
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 60 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-06-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-[[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]methylamino]-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

FS STEREOSEARCH
MF C38 H62 N4 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 61 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-04-4 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N,3-dimethyl-N-[(1S,2E)-3-methyl-1-(1-methylethyl)-4-oxo-4-[(2-phenylethyl)amino]-2-butenyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H52 N4 O3
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 62 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-02-2 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-[(4-azidophenyl)amino]-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C33 H47 N7 O3 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676635-01-1
CMF C33 H47 N7 O3

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 63 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676635-01-1 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-[(4-azidophenyl)amino]-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

FS STEREOSEARCH
MF C33 H47 N7 O3
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 64 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-96-1 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-[(2-cyanoethyl)amino]-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H47 N5 O3 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676634-95-0
CMF C30 H47 N5 O3

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1

CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 65 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-95-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-[(2-cyanoethyl)amino]-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H47 N5 O3
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 66 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-93-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N,3-dimethyl-N-[(1S,2E)-3-methyl-4-(methylamino)-1-(1-methylethyl)-4-oxo-2-butenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H46 N4 O3 . C2 H F3 O2
SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

CM 1

CRN 676634-92-7
CMF C28 H46 N4 O3

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 67 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-92-7 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N,3-dimethyl-N-[(1S,2E)-3-methyl-4-(methylamino)-1-(1-methylethyl)-4-oxo-2-butenyl]-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H46 N4 O3
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 68 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-90-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-amino-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H44 N4 O3 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

CM 1

CRN 676634-89-2
CMF C27 H44 N4 O3

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 69 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-89-2 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-amino-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H44 N4 O3
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 70 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-84-7 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H41 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676634-83-6
CMF C26 H41 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 71 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-83-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H41 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 72 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-81-4 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(2-methylpropyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676634-80-3
CMF C28 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 73 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-80-3 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(2-methylpropyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 74 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-75-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H39 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676634-74-5
CMF C25 H39 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 75 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-74-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H39 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 76 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-71-2 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β-dimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H41 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676634-70-1
CMF C26 H41 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 77 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-70-1 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β-dimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H41 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 78 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-52-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-ethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H43 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676634-51-8
CMF C27 H43 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 79 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-51-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-ethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H43 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 80 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-48-3 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-ethyl-3-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676634-47-2
CMF C28 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 81 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-47-2 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-ethyl-3-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 82 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-44-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(2-methylpropyl)-2-butenyl]-3-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H43 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676634-43-8

CMF C27 H43 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 83 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-43-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(2-methylpropyl)-2-butenyl]-3-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H43 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 84 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-40-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(2-methylpropyl)-2-butenyl]-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H43 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676634-39-2
CMF C27 H43 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 85 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-39-2 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(2-methylpropyl)-2-butenyl]-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H43 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 86 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-36-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 4-benzoyl-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C34 H47 N3 O5 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676634-35-8
CMF C34 H47 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 87 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-35-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 4-benzoyl-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C34 H47 N3 O5
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 88 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-11-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl-3-(methylthio)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O5 S . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676634-10-9
CMF C28 H45 N3 O5 S

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 89 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-10-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl-3-(methylthio)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O5 S
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 90 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-07-4 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-[[(4-methoxyphenyl)methyl]thio]-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H51 N3 O6 S . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676634-06-3
CMF C35 H51 N3 O6 S

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 91 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-06-3 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-[[(4-methoxyphenyl)methyl]thio]-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H51 N3 O6 S
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 92 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-03-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-[[(4-methoxyphenyl)methyl]thio]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C34 H49 N3 O5 S . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (676636-82-1)

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 93 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676634-00-7 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl-3-(methylsulfonyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H43 N3 O6 S . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676633-99-1
CMF C27 H43 N3 O6 S

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 94 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-99-1 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH
MF C27 H43 N3 O6 S
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 95 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-96-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl-3-(methylthio)-, monohydrochloride (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H43 N3 O4 S . Cl H
SR CA
LC STN Files: CA, CAPLUS, SYNTHLINE, TOXCENTER, USPATFULL
CRN (676636-79-6)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 96 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-93-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N-methyl-3-(methylthio)-, monohydrochloride (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H47 N3 O4 S . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (676636-77-4)

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 97 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-90-2 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-pentenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676633-89-9
CMF C28 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 98 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-89-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-pentenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 99 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-86-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-heptenyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H47 N3 O4 . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (676637-30-2)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 100 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-83-3 REGISTRY

ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(2-methylpropyl)-2-pentenyl]-N,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H47 N3 O4 . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (676637-28-8)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 101 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-80-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S)-1-[(1E)-2-carboxy-1-propenyl]pentyl]-N,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4 . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (676637-26-6)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 102 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-73-1 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N-methyl-2-(1-phenylcyclohexyl)glycyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H47 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676633-72-0
CMF C30 H47 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 103 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-72-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N-methyl-2-(1-phenylcyclohexyl)glycyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H47 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 104 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-69-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, (2R)-N-methyl-2-(1-phenylcyclopentyl)glycyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H45 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676633-68-4

CMF C29 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 105 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-68-4 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, (2R)-N-methyl-2-(1-phenylcyclopentyl)glycyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H45 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 106 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-65-1 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, (2S)-N-methyl-2-(1-phenylcyclopentyl)glycyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H45 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

CM 1

CRN 676633-64-0
CMF C29 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 107 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN

RN 676633-64-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, (2S)-N-methyl-2-(1-phenylcyclopentyl)glycyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H45 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 108 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-61-7 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-cyclohexyl-N-methyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H49 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

CM 1

CRN 676633-60-6
CMF C27 H49 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 109 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-60-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-cyclohexyl-N-methyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H49 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 110 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-57-1 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-O-(1-methylethyl)-D-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

FS STEREOSEARCH
MF C30 H49 N3 O5 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676633-56-0
CMF C30 H49 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 111 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-56-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-O-(1-methylethyl)-D-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H49 N3 O5
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 112 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-53-7 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-O-(1-methylethyl)-L-tyrosyl-N-{(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl}-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H49 N3 O5 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676633-52-6
CMF C30 H49 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 113 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-52-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-O-(1-methylethyl)-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H49 N3 O5
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 114 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-49-1 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-3,5-bis(trifluoromethyl)-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H41 F6 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676633-48-0
CMF C29 H41 F6 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 115 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-48-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-3,5-bis(trifluoromethyl)-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H41 F6 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 116 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-46-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-3,5-bis(trifluoromethyl)-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H41 F6 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676633-45-7
CMF C29 H41 F6 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 117 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-45-7 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-3,5-bis(trifluoromethyl)-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H41 F6 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 118 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-43-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3,5-difluoro-N,β,β-trimethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H41 F2 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676633-42-4
CMF C27 H41 F2 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 119 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-42-4 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3,5-difluoro-N,β,β-trimethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H41 F2 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 120 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-40-2 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3,5-difluoro-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H41 F2 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676633-39-9
CMF C27 H41 F2 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 121 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-39-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3,5-difluoro-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H41 F2 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 122 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-34-4 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-3-(trifluoromethyl)-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H42 F3 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676633-33-3
CMF C28 H42 F3 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 123 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-33-3 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β-trimethyl-3-(trifluoromethyl)-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H42 F3 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 124 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-29-7 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-fluoro-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H42 F N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676633-28-6
CMF C27 H42 F N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 125 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-28-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-fluoro-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H42 F N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 126 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-26-4 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 2-methoxy-N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H47 N3 O6 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676633-25-3
CMF C29 H47 N3 O6

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 127 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-25-3 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 2-methoxy-N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H47 N3 O6
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 128 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-22-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 2-methoxy-N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H51 N3 O6 . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (676637-03-9)

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 129 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-19-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

FS STEREOSEARCH
MF C28 H45 N3 O5 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL

CM 1

CRN 676633-18-4
CMF C28 H45 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 130 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-18-4 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O5
CI COM
SR CA
LC STN Files: CA, CAPLUS, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL

Absolute stereochemistry.

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 131 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-16-2 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H49 N3 O5 . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (676637-00-6)

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 132 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-13-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 2-methoxy-N,β,β-trimethyl-L-phenylalanyl-N-

[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

FS STEREOSEARCH
MF C28 H45 N3 O5 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676633-12-8
CMF C28 H45 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 133 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-12-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 2-methoxy-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O5
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 134 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-09-3 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 2-methoxy-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H49 N3 O5 . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (676636-97-8)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 135 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-06-0 REGISTRY
ED Entered STN: 26 Apr 2004

CN L-Valinamide, N-(2-hydroxyethyl)-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H47 N3 O5
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 136 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-03-7 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,N,β,β-tetramethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 137 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676633-01-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N-methyl-3-pentyl-D-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H49 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 138 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-99-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N-methyl-3-pentyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H49 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 139 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-97-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,3-dimethyl-4-phenyl-D-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 140 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-94-3 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,3-dimethyl-4-phenyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 141 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-91-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-hydroxy-N,β,β-trimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H43 N3 O5 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676632-90-9
CMF C27 H43 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 142 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-90-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-hydroxy-N,β,β-trimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H43 N3 O5
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 143 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-87-4 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-methoxy-N,β,β-trimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O5 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676632-86-3
CMF C28 H45 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 144 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-86-3 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-methoxy-N,β,β-trimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O5
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 145 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-83-0 REGISTRY
ED Entered STN: 26 Apr 2004

CN L-Valinamide, 4-carboxy-N,β,β-trimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H43 N3 O6 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676632-82-9
CMF C28 H43 N3 O6

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 146 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-82-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 4-carboxy-N,β,β-trimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H43 N3 O6
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 147 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-79-4 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-[1,1'-biphenyl]-4-yl-N-methyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C33 H47 N3 O4 . 2 C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676632-78-3
CMF C33 H47 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 148 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-78-3 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-[1,1'-biphenyl]-4-yl-N-methyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C33 H47 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 149 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-76-1 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 4-bromo-N,β,β-trimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H42 Br N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676632-75-0
CMF C27 H42 Br N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 150 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-75-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 4-bromo-N,β,β-trimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H42 Br N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 151 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-72-7 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-ethyl-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H47 N3 O4 . 2 C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676632-71-6
CMF C29 H47 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 152 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-71-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-ethyl-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H47 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 153 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-69-2 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-ethenyl-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H45 N3 O4 . 3/2 C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676632-68-1
CMF C29 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 154 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-68-1 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-ethenyl-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H45 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 155 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-66-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-[1,1'-biphenyl]-3-yl-N-methyl-D-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C33 H47 N3 O4 . 2 C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676632-65-8
CMF C33 H47 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 156 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-65-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-[1,1'-biphenyl]-3-yl-N-methyl-D-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C33 H47 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 157 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-62-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-[1,1'-biphenyl]-3-yl-N-methyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C33 H47 N3 O4 . 2 C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676632-61-4
CMF C33 H47 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 158 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-61-4 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-[1,1'-biphenyl]-3-yl-N-methyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C33 H47 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 159 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-59-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-bromo-N,β,β-trimethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H42 Br N3 O4 . 2 C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676632-58-9
CMF C27 H42 Br N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 160 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-58-9 REGISTRY

ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-bromo-N,β,β-trimethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H42 Br N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 161 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-56-7 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-bromo-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H42 Br N3 O4 . 2 C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676632-55-6
CMF C27 H42 Br N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 162 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-55-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-bromo-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-buten-1-yl]-N,3-dimethyl- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Valinamide, 3-bromo-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI)
FS STEREOSEARCH
MF C27 H42 Br N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 163 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-53-4 REGISTRY

ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,2-tetramethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 164 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-51-2 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,2-tetramethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 165 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-48-7 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,2-tetramethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H49 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 166 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-45-4 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-N,β,β,2-tetramethylphenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H57 N3 O6
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 167 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-42-1 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N-ethyl-β,β-dimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 168 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-40-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N-ethyl-β,β-dimethylphenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H49 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 169 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-38-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 4-(1,1-dimethylethyl)-N,β,β-trimethylphenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C33 H55 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 170 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-33-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-benzo[b]thien-2-yl-N-methylvalyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H43 N3 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 171 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-31-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-benzo[b]thien-2-yl-N-methylvalyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H47 N3 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 172 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-28-3 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-benzo[b]thien-3-yl-N-methylvalyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H47 N3 O4 S

SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 173 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-25-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N-methyl-3-(3-thienyl)-D-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H41 N3 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 174 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-22-7 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N-methyl-3-(3-thienyl)-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH

MF C25 H41 N3 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 175 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-20-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N-methyl-3-(3-thienyl)-L-valyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H45 N3 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 176 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-17-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N-methyl-3-(2-thienyl)-D-valyl-N-[(1S,2E)-3-carboxy-1-

(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H41 N3 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 177 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-14-7 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N-methyl-3-(2-thienyl)-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H41 N3 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 178 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-11-4 REGISTRY
ED Entered STN: 26 Apr 2004

CN L-Valinamide, N-methyl-3-(2-thienyl)-L-valyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H45 N3 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 179 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-08-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,3,5-pentamethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H47 N3 O4
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 180 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-05-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,3,5-pentamethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H47 N3 O4
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 181 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-03-4 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,3,5-pentamethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H51 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 182 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676632-00-1 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,3,4-pentamethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H47 N3 O4
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 183 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-97-3 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,3,4-pentamethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H47 N3 O4
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 184 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-94-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,3,4-pentamethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H51 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 185 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-92-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,4-tetramethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676631-91-7
CMF C28 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 186 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-91-7 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,4-tetramethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 187 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-89-3 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,4-tetramethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676631-88-2
CMF C28 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 188 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-88-2 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,4-tetramethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 189 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-86-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,4-tetramethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H49 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 190 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-84-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,3-tetramethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 191 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-81-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,3-tetramethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H45 N3 O4
CI COM

SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 192 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-78-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,3-tetramethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H49 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 193 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-76-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 4-chloro-N,β,β-trimethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI)

(CA INDEX NAME)
FS STEREOSEARCH
MF C27 H42 Cl N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 194 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-74-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 4-chloro-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI)
(CA INDEX NAME)
FS STEREOSEARCH
MF C27 H42 Cl N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 195 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-71-3 REGISTRY

ED Entered STN: 26 Apr 2004
CN L-Valinamide, 4-chloro-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H46 Cl N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 196 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-68-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-chloro-N,β,β-trimethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H42 Cl N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 197 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-65-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-chloro-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H42 Cl N3 O4
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 198 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-63-3 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-chloro-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H46 Cl N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 199 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-61-1 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-benzo[b]thien-3-yl-N-methylvalyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H43 N3 O4 S . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 676631-60-0
CMF C29 H43 N3 O4 S

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 200 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-60-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-benzo[b]thien-3-yl-N-methylvalyl-N-[(1S,2E)-3-carboxy-

1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H43 N3 O4 S
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 201 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-57-5 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,2-tetramethyl-D-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H49 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 202 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN

RN 676631-55-3 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N-methyl-3-(3-thienyl)-D-valyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H45 N3 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 203 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-52-0 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N-methyl-3-(2-thienyl)-D-valyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H45 N3 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 204 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-50-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,3,5-pentamethyl-D-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H51 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 205 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-47-3 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,3,4-pentamethyl-D-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H51 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 206 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-44-9 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,4-tetramethyl-D-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H49 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 207 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-42-8 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, N,β,β,3-tetramethyl-D-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H49 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 208 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-40-6 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 4-chloro-N,β,β-trimethyl-D-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H46 Cl N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L45 ANSWER 209 OF 209 REGISTRY COPYRIGHT 2009 ACS on STN
RN 676631-37-1 REGISTRY
ED Entered STN: 26 Apr 2004
CN L-Valinamide, 3-chloro-N,β,β-trimethyl-D-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H46 Cl N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

******* QUERY RESULTS *******

(COMPOUNDS FROM CLAIMS 28-51 AND OVARIAN CANCERS)

```
=> d his l50

     (FILE 'HCAPLUS' ENTERED AT 08:29:36 ON 10 MAR 2009)
L50             0 S L46 AND L49

=> d que l50
L1             12 SEA FILE=REGISTRY ABB=ON  PLU=ON  (676633-01-5/RN OR 676633-02-
                  6/RN OR 676633-03-7/RN OR 676633-04-8/RN OR 676633-05-9/RN OR
                  676633-06-0/RN OR 676633-07-1/RN OR 676633-08-2/RN OR 676633-09
                  -3/RN OR 676633-10-6/RN OR 676633-11-7/RN OR 676633-12-8/RN)
L3              5 SEA FILE=REGISTRY ABB=ON  PLU=ON  L1 AND "L()VALINAMIDE"
L4             22 SEA FILE=REGISTRY ABB=ON  PLU=ON  (676633-13-9/RN OR 676633-14-
                  0/RN OR 676633-15-1/RN OR 676633-16-2/RN OR 676633-17-3/RN OR
                  676633-18-4/RN OR 676633-19-5/RN OR 676633-20-8/RN OR 676633-21
                  -9/RN OR 676633-22-0/RN OR 676633-23-1/RN OR 676633-24-2/RN OR
                  676633-25-3/RN OR 676633-26-4/RN OR 676633-27-5/RN OR 676633-28
                  -6/RN OR 676633-29-7/RN OR 676633-30-0/RN OR 676633-31-1/RN OR
                  676633-32-2/RN OR 676633-33-3/RN OR 676633-34-4/RN)
L5             11 SEA FILE=REGISTRY ABB=ON  PLU=ON  L4 AND "L()VALINAMIDE"
L6             22 SEA FILE=REGISTRY ABB=ON  PLU=ON  (676633-39-9/RN OR 676633-40-
                  2/RN OR 676633-41-3/RN OR 676633-42-4/RN OR 676633-43-5/RN OR
                  676633-44-6/RN OR 676633-45-7/RN OR 676633-46-8/RN OR 676633-47
                  -9/RN OR 676633-48-0/RN OR 676633-49-1/RN OR 676633-50-4/RN OR
                  676633-51-5/RN OR 676633-52-6/RN OR 676633-53-7/RN OR 676633-54
                  -8/RN OR 676633-55-9/RN OR 676633-56-0/RN OR 676633-57-1/RN OR
                  676633-58-2/RN OR 676633-59-3/RN OR 676633-60-6/RN)
L7             13 SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 AND "L()VALINAMIDE"
L9             20 SEA FILE=REGISTRY ABB=ON  PLU=ON  (676633-61-7/RN OR 676633-62-
                  8/RN OR 676633-63-9/RN OR 676633-64-0/RN OR 676633-65-1/RN OR
                  676633-66-2/RN OR 676633-67-3/RN OR 676633-68-4/RN OR 676633-69
                  -5/RN OR 676633-70-8/RN OR 676633-71-9/RN OR 676633-72-0/RN OR
                  676633-73-1/RN OR 676633-74-2/RN OR 676633-75-3/RN OR 676633-76
                  -4/RN OR 676633-77-5/RN OR 676633-78-6/RN OR 676633-79-7/RN OR
                  676633-80-0/RN)
L10             8 SEA FILE=REGISTRY ABB=ON  PLU=ON  L9 AND "L()VALINAMIDE"
L13            46 SEA FILE=REGISTRY ABB=ON  PLU=ON  (676633-83-3/RN OR 676633-84-
                  4/RN OR 676633-85-5/RN OR 676633-86-6/RN OR 676633-87-7/RN OR
                  676633-88-8/RN OR 676633-89-9/RN OR 676633-90-2/RN OR 676633-91
                  -3/RN OR 676633-92-4/RN OR 676633-93-5/RN OR 676633-94-6/RN OR
                  676633-95-7/RN OR 676633-96-8/RN OR 676633-97-9/RN OR 676633-98
                  -0/RN OR 676633-99-1/RN OR 676634-00-7/RN OR 676634-01-8/RN OR
                  676634-02-9/RN OR 676634-03-0/RN OR 676634-04-1/RN OR 676634-05
                  -2/RN OR 676634-06-3/RN OR 676634-07-4/RN OR 676634-08-5/RN OR
                  676634-09-6/RN OR 676634-10-9/RN OR 676634-11-0/RN OR 676634-12
                  -1/RN OR 676634-13-2/RN OR 676634-14-3/RN OR 676634-15-4/RN OR
                  676634-16-5/RN OR 676634-17-6/RN OR 676634-18-7/RN OR 676634-19
                  -8/RN OR 676634-20-1/RN OR 676634-21-2/RN OR 676634-22-3/RN OR
                  676634-23-4/RN OR 676634-24-5/RN OR 676634-25-6/RN OR 676634-26
                  -7/RN OR 676634-27-8/RN OR 676634-28-9/RN)
L14            13 SEA FILE=REGISTRY ABB=ON  PLU=ON  L13 AND "L()VALINAMIDE"
L15            45 SEA FILE=REGISTRY ABB=ON  PLU=ON  (676634-31-4/RN OR 676634-32-
                  5/RN OR 676634-33-6/RN OR 676634-34-7/RN OR 676634-35-8/RN OR
                  676634-36-9/RN OR 676634-37-0/RN OR 676634-38-1/RN OR 676634-39
                  -2/RN OR 676634-40-5/RN OR 676634-41-6/RN OR 676634-42-7/RN OR
                  676634-43-8/RN OR 676634-44-9/RN OR 676634-45-0/RN OR 676634-46
                  -1/RN OR 676634-47-2/RN OR 676634-48-3/RN OR 676634-49-4/RN OR
                  676634-50-7/RN OR 676634-51-8/RN OR 676634-52-9/RN OR 676634-53
```

-0/RN OR 676634-54-1/RN OR 676634-55-2/RN OR 676634-56-3/RN OR 676634-57-4/RN OR 676634-58-5/RN OR 676634-59-6/RN OR 676634-60-9/RN OR 676634-61-0/RN OR 676634-62-1/RN OR 676634-63-2/RN OR 676634-64-3/RN OR 676634-65-4/RN OR 676634-66-5/RN OR 676634-67-6/RN OR 676634-68-7/RN OR 676634-69-8/RN OR 676634-70-1/RN OR 676634-71-2/RN OR 676634-72-3/RN OR 676634-73-4/RN OR 676634-74-5/RN OR 676634-75-6/RN)

L16 14 SEA FILE=REGISTRY ABB=ON PLU=ON L15 AND "L()VALINAMIDE"

L20 58 SEA FILE=REGISTRY ABB=ON PLU=ON (676634-77-8/RN OR 676634-78-9/RN OR 676634-79-0/RN OR 676634-80-3/RN OR 676634-81-4/RN OR 676634-82-5/RN OR 676634-83-6/RN OR 676634-84-7/RN OR 676634-85-8/RN OR 676634-86-9/RN OR 676634-87-0/RN OR 676634-88-1/RN OR 676634-89-2/RN OR 676634-90-5/RN OR 676634-91-6/RN OR 676634-92-7/RN OR 676634-93-8/RN OR 676634-94-9/RN OR 676634-95-0/RN OR 676634-96-1/RN OR 676634-97-2/RN OR 676634-98-3/RN OR 676634-99-4/RN OR 676635-00-0/RN OR 676635-01-1/RN OR 676635-02-2/RN OR 676635-03-3/RN OR 676635-04-4/RN OR 676635-05-5/RN OR 676635-06-6/RN OR 676635-07-7/RN OR 676635-08-8/RN OR 676635-09-9/RN OR 676635-10-2/RN OR 676635-11-3/RN OR 676635-12-4/RN OR 676635-13-5/RN OR 676635-14-6/RN OR 676635-15-7/RN OR 676635-16-8/RN OR 676635-17-9/RN OR 676635-18-0/RN OR 676635-19-1/RN OR 676635-20-4/RN OR 676635-21-5/RN OR 676635-22-6/RN OR 676635-23-7/RN OR 676635-24-8/RN OR 676635-25-9/RN OR 676635-26-0/RN OR 676635-27-1/RN OR 676635-28-2/RN OR 676635-29-3/RN OR 676635-30-6/RN OR 676635-31-7/RN OR 676635-32-8/RN OR 676635-33-9/RN OR 676635-34-0/RN)

L21 25 SEA FILE=REGISTRY ABB=ON PLU=ON L20 AND "L()VALINAMIDE"

L22 67 SEA FILE=REGISTRY ABB=ON PLU=ON (676635-33-9/RN OR 676635-34-0/RN OR 676635-35-1/RN OR 676635-36-2/RN OR 676635-37-3/RN OR 676635-38-4/RN OR 676635-39-5/RN OR 676635-40-8/RN OR 676635-41-9/RN OR 676635-42-0/RN OR 676635-43-1/RN OR 676635-44-2/RN OR 676635-45-3/RN OR 676635-46-4/RN OR 676635-47-5/RN OR 676635-48-6/RN OR 676635-49-7/RN OR 676635-50-0/RN OR 676635-51-1/RN OR 676635-52-2/RN OR 676635-53-3/RN OR 676635-54-4/RN OR 676635-55-5/RN OR 676635-56-6/RN OR 676635-57-7/RN OR 676635-58-8/RN OR 676635-59-9/RN OR 676635-60-2/RN OR 676635-61-3/RN OR 676635-62-4/RN OR 676635-63-5/RN OR 676635-64-6/RN OR 676635-65-7/RN OR 676635-66-8/RN OR 676635-67-9/RN OR 676635-68-0/RN OR 676635-69-1/RN OR 676635-70-4/RN OR 676635-71-5/RN OR 676635-72-6/RN OR 676635-73-7/RN OR 676635-74-8/RN OR 676635-75-9/RN OR 676635-76-0/RN OR 676635-77-1/RN OR 676635-78-2/RN OR 676635-79-3/RN OR 676635-80-6/RN OR 676635-81-7/RN OR 676635-82-8/RN OR 676635-83-9/RN OR 676635-84-0/RN OR 676635-85-1/RN OR 676635-86-2/RN OR 676635-87-3/RN OR 676635-88-4/RN OR 676635-89-5/RN OR 676635-90-8/RN OR 676635-91-9/RN OR 676635-92-0/RN OR 676635-93-1/RN OR 676635-94-2/RN OR 676635-95-3/RN OR 676635-96-4/RN OR 676635-97-5/RN OR 676635-98-6/RN OR 676635-99-7/RN)

L23 21 SEA FILE=REGISTRY ABB=ON PLU=ON L22 AND "L()VALINAMIDE"

L25 1 SEA FILE=REGISTRY ABB=ON PLU=ON L22 AND LEUCINAMIDE

L27 27 SEA FILE=REGISTRY ABB=ON PLU=ON (676636-02-5/RN OR 676636-03-6/RN OR 676636-04-7/RN OR 676636-05-8/RN OR 676636-06-9/RN OR 676636-07-0/RN OR 676636-08-1/RN OR 676636-09-2/RN OR 676636-10-5/RN OR 676636-11-6/RN OR 676636-12-7/RN OR 676636-13-8/RN OR 676636-14-9/RN OR 676636-15-0/RN OR 676636-16-1/RN OR 676636-17-2/RN OR 676636-18-3/RN OR 676636-19-4/RN OR 676636-20-7/RN OR 676636-21-8/RN OR 676636-22-9/RN OR 676636-23-0/RN OR 676636-24-1/RN OR 676636-25-2/RN OR 676636-26-3/RN OR 676636-27-4/RN OR 676636-28-5/RN)

L28 14 SEA FILE=REGISTRY ABB=ON PLU=ON L27 AND "L()VALINAMIDE"

L29 22 SEA FILE=REGISTRY ABB=ON PLU=ON (676636-77-4/RN OR 676636-78-

5/RN OR 676636-79-6/RN OR 676636-80-9/RN OR 676636-81-0/RN OR 676636-82-1/RN OR 676636-83-2/RN OR 676636-84-3/RN OR 676636-85-4/RN OR 676636-86-5/RN OR 676636-87-6/RN OR 676636-88-7/RN OR 676636-89-8/RN OR 676636-90-1/RN OR 676636-91-2/RN OR 676636-92-3/RN OR 676636-93-4/RN OR 676636-94-5/RN OR 676636-95-6/RN OR 676636-96-7/RN OR 676636-97-8/RN OR 676636-98-9/RN)

L30 4 SEA FILE=REGISTRY ABB=ON PLU=ON L29 AND "L()VALINAMIDE"

L31 29 SEA FILE=REGISTRY ABB=ON PLU=ON (676637-00-6/RN OR 676637-01-7/RN OR 676637-02-8/RN OR 676637-03-9/RN OR 676637-04-0/RN OR 676637-05-1/RN OR 676637-06-2/RN OR 676637-07-3/RN OR 676637-08-4/RN OR 676637-09-5/RN OR 676637-10-8/RN OR 676637-11-9/RN OR 676637-12-0/RN OR 676637-13-1/RN OR 676637-14-2/RN OR 676637-15-3/RN OR 676637-16-4/RN OR 676637-17-5/RN OR 676637-18-6/RN OR 676637-19-7/RN OR 676637-20-0/RN OR 676637-21-1/RN OR 676637-22-2/RN OR 676637-23-3/RN OR 676637-24-4/RN OR 676637-25-5/RN OR 676637-26-6/RN OR 676637-27-7/RN OR 676637-28-8/RN)

L32 8 SEA FILE=REGISTRY ABB=ON PLU=ON L31 AND "L()VALINAMIDE"

L33 70 SEA FILE=REGISTRY ABB=ON PLU=ON (676631-37-1/RN OR 676631-38-2/RN OR 676631-39-3/RN OR 676631-40-6/RN OR 676631-41-7/RN OR 676631-42-8/RN OR 676631-43-9/RN OR 676631-44-0/RN OR 676631-45-1/RN OR 676631-46-2/RN OR 676631-47-3/RN OR 676631-48-4/RN OR 676631-49-5/RN OR 676631-50-8/RN OR 676631-51-9/RN OR 676631-52-0/RN OR 676631-53-1/RN OR 676631-54-2/RN OR 676631-55-3/RN OR 676631-56-4/RN OR 676631-57-5/RN OR 676631-58-6/RN OR 676631-59-7/RN OR 676631-60-0/RN OR 676631-61-1/RN OR 676631-62-2/RN OR 676631-63-3/RN OR 676631-64-4/RN OR 676631-65-5/RN OR 676631-66-6/RN OR 676631-67-7/RN OR 676631-68-8/RN OR 676631-69-9/RN OR 676631-70-2/RN OR 676631-71-3/RN OR 676631-72-4/RN OR 676631-73-5/RN OR 676631-74-6/RN OR 676631-75-7/RN OR 676631-76-8/RN OR 676631-77-9/RN OR 676631-78-0/RN OR 676631-79-1/RN OR 676631-80-4/RN OR 676631-81-5/RN OR 676631-82-6/RN OR 676631-83-7/RN OR 676631-84-8/RN OR 676631-85-9/RN OR 676631-86-0/RN OR 676631-87-1/RN OR 676631-88-2/RN OR 676631-89-3/RN OR 676631-90-6/RN OR 676631-91-7/RN OR 676631-92-8/RN OR 676631-93-9/RN OR 676631-94-0/RN OR 676631-95-1/RN OR 676631-96-2/RN OR 676631-97-3/RN OR 676631-98-4/RN OR 676631-99-5/RN OR 676632-00-1/RN OR 676632-01-2/RN OR 676632-02-3/RN OR 676632-03-4/RN OR 676632-04-5/RN OR 676632-05-6/RN OR 676632-06-7/RN)

L34 30 SEA FILE=REGISTRY ABB=ON PLU=ON L33 AND "L()VALINAMIDE"

L35 108 SEA FILE=REGISTRY ABB=ON PLU=ON (676632-05-6/RN OR 676632-06-7/RN OR 676632-07-8/RN OR 676632-08-9/RN OR 676632-09-0/RN OR 676632-10-3/RN OR 676632-11-4/RN OR 676632-12-5/RN OR 676632-13-6/RN OR 676632-14-7/RN OR 676632-15-8/RN OR 676632-16-9/RN OR 676632-17-0/RN OR 676632-18-1/RN OR 676632-19-2/RN OR 676632-20-5/RN OR 676632-21-6/RN OR 676632-22-7/RN OR 676632-23-8/RN OR 676632-24-9/RN OR 676632-25-0/RN OR 676632-26-1/RN OR 676632-27-2/RN OR 676632-28-3/RN OR 676632-29-4/RN OR 676632-30-7/RN OR 676632-31-8/RN OR 676632-32-9/RN OR 676632-33-0/RN OR 676632-34-1/RN OR 676632-35-2/RN OR 676632-36-3/RN OR 676632-37-4/RN OR 676632-38-5/RN OR 676632-39-6/RN OR 676632-40-9/RN OR 676632-41-0/RN OR 676632-42-1/RN OR 676632-43-2/RN OR 676632-44-3/RN OR 676632-45-4/RN OR 676632-46-5/RN OR 676632-47-6/RN OR 676632-48-7/RN OR 676632-49-8/RN OR 676632-50-1/RN OR 676632-51-2/RN OR 676632-52-3/RN OR 676632-53-4/RN OR 676632-54-5/RN OR 676632-55-6/RN OR 676632-56-7/RN OR 676632-57-8/RN OR 676632-58-9/RN OR 676632-59-0/RN OR 676632-60-3/RN OR 676632-61-4/RN OR 676632-62-5/RN OR 676632-63-6/RN OR 676632-64-7/RN OR 676632-65-8/RN OR 676632-66-9/RN OR 676632-67-0/RN OR 676632-68-1/RN OR 676632-69-2/RN OR 676632-70-5/RN OR 676632-71-6/RN OR 676632-72-7/RN OR 676632-73-8/RN OR 676632-74-9/RN OR 676632-75-0/RN OR 676632-76

-1/RN OR 676632-77-2/RN OR 676632-78-3/RN OR 676632-79-4/RN OR 676632-80-7/RN OR 676632-81-8/RN OR 676632-82-9/RN OR 676632-83-0/RN OR 676632-84-1/RN OR 676632-85-2/RN OR 676632-86-3/RN OR 676632-87-4/RN OR 676632-88-5/RN OR 676632-89-6/RN OR 676632-90-9/RN OR 676632-91-0/RN OR 676632-92-1/RN OR 676632-93-2/RN OR 676632-94-3/RN OR 676632-95-4/RN OR 676632-96-5/RN OR 676632-97-6/RN OR 676632-98-7/RN OR 676632-99-8/RN OR 676633-00-4/RN OR 676633-01-5/RN OR 676633-02-6/RN OR 676633-03-7/RN OR 676633-04-8/RN OR 676633-05-9/RN OR 676633-06-0/RN OR 676633-07-1/RN OR 676633-08-2/RN OR 676633-09-3/RN OR 676633-10-6/RN OR 676633-11-7/RN OR 676633-12-8/RN)

L36 48 SEA FILE=REGISTRY ABB=ON PLU=ON L35 AND "L()VALINAMIDE"

L45 209 SEA FILE=REGISTRY ABB=ON PLU=ON L3 OR L5 OR L7 OR L10 OR L14 OR L16 OR L21 OR L23 OR L25 OR L28 OR L30 OR L32 OR L34 OR L36

L46 11 SEA FILE=HCAPLUS ABB=ON PLU=ON L45

L49 36120 SEA FILE=HCAPLUS ABB=ON PLU=ON (OVAR?) (S) (CANCER? OR NEOPLAS? OR TUMOR? OR TUMOUR? OR CARCIN?)

L50 0 SEA FILE=HCAPLUS ABB=ON PLU=ON L46 AND L49

```
=> d his l56

     (FILE 'HCAPLUS' ENTERED AT 08:29:36 ON 10 MAR 2009)
L56            8 S L51 OR L55
                 SAVE TEMP L56 JEA722HCAP1/A

     FILE 'REGISTRY' ENTERED AT 08:37:10 ON 10 MAR 2009
                 SAVE TEMP L45 JEA722ALLCOM/A

         FILE 'STNGUIDE' ENTERED AT 08:42:13 ON 10 MAR 2009

=> d que l56
L1            12 SEA FILE=REGISTRY ABB=ON  PLU=ON  (676633-01-5/RN OR 676633-02-
                 6/RN OR 676633-03-7/RN OR 676633-04-8/RN OR 676633-05-9/RN OR
                 676633-06-0/RN OR 676633-07-1/RN OR 676633-08-2/RN OR 676633-09
                 -3/RN OR 676633-10-6/RN OR 676633-11-7/RN OR 676633-12-8/RN)
L3             5 SEA FILE=REGISTRY ABB=ON  PLU=ON  L1 AND "L()VALINAMIDE"
L4            22 SEA FILE=REGISTRY ABB=ON  PLU=ON  (676633-13-9/RN OR 676633-14-
                 0/RN OR 676633-15-1/RN OR 676633-16-2/RN OR 676633-17-3/RN OR
                 676633-18-4/RN OR 676633-19-5/RN OR 676633-20-8/RN OR 676633-21
                 -9/RN OR 676633-22-0/RN OR 676633-23-1/RN OR 676633-24-2/RN OR
                 676633-25-3/RN OR 676633-26-4/RN OR 676633-27-5/RN OR 676633-28
                 -6/RN OR 676633-29-7/RN OR 676633-30-0/RN OR 676633-31-1/RN OR
                 676633-32-2/RN OR 676633-33-3/RN OR 676633-34-4/RN)
L5            11 SEA FILE=REGISTRY ABB=ON  PLU=ON  L4 AND "L()VALINAMIDE"
L6            22 SEA FILE=REGISTRY ABB=ON  PLU=ON  (676633-39-9/RN OR 676633-40-
                 2/RN OR 676633-41-3/RN OR 676633-42-4/RN OR 676633-43-5/RN OR
                 676633-44-6/RN OR 676633-45-7/RN OR 676633-46-8/RN OR 676633-47
                 -9/RN OR 676633-48-0/RN OR 676633-49-1/RN OR 676633-50-4/RN OR
                 676633-51-5/RN OR 676633-52-6/RN OR 676633-53-7/RN OR 676633-54
                 -8/RN OR 676633-55-9/RN OR 676633-56-0/RN OR 676633-57-1/RN OR
                 676633-58-2/RN OR 676633-59-3/RN OR 676633-60-6/RN)
L7            13 SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 AND "L()VALINAMIDE"
L9            20 SEA FILE=REGISTRY ABB=ON  PLU=ON  (676633-61-7/RN OR 676633-62-
                 8/RN OR 676633-63-9/RN OR 676633-64-0/RN OR 676633-65-1/RN OR
                 676633-66-2/RN OR 676633-67-3/RN OR 676633-68-4/RN OR 676633-69
                 -5/RN OR 676633-70-8/RN OR 676633-71-9/RN OR 676633-72-0/RN OR
                 676633-73-1/RN OR 676633-74-2/RN OR 676633-75-3/RN OR 676633-76
                 -4/RN OR 676633-77-5/RN OR 676633-78-6/RN OR 676633-79-7/RN OR
                 676633-80-0/RN)
L10            8 SEA FILE=REGISTRY ABB=ON  PLU=ON  L9 AND "L()VALINAMIDE"
L13           46 SEA FILE=REGISTRY ABB=ON  PLU=ON  (676633-83-3/RN OR 676633-84-
                 4/RN OR 676633-85-5/RN OR 676633-86-6/RN OR 676633-87-7/RN OR
                 676633-88-8/RN OR 676633-89-9/RN OR 676633-90-2/RN OR 676633-91
                 -3/RN OR 676633-92-4/RN OR 676633-93-5/RN OR 676633-94-6/RN OR
                 676633-95-7/RN OR 676633-96-8/RN OR 676633-97-9/RN OR 676633-98
                 -0/RN OR 676633-99-1/RN OR 676634-00-7/RN OR 676634-01-8/RN OR
                 676634-02-9/RN OR 676634-03-0/RN OR 676634-04-1/RN OR 676634-05
                 -2/RN OR 676634-06-3/RN OR 676634-07-4/RN OR 676634-08-5/RN OR
                 676634-09-6/RN OR 676634-10-9/RN OR 676634-11-0/RN OR 676634-12
                 -1/RN OR 676634-13-2/RN OR 676634-14-3/RN OR 676634-15-4/RN OR
                 676634-16-5/RN OR 676634-17-6/RN OR 676634-18-7/RN OR 676634-19
                 -8/RN OR 676634-20-1/RN OR 676634-21-2/RN OR 676634-22-3/RN OR
                 676634-23-4/RN OR 676634-24-5/RN OR 676634-25-6/RN OR 676634-26
                 -7/RN OR 676634-27-8/RN OR 676634-28-9/RN)
L14           13 SEA FILE=REGISTRY ABB=ON  PLU=ON  L13 AND "L()VALINAMIDE"
L15           45 SEA FILE=REGISTRY ABB=ON  PLU=ON  (676634-31-4/RN OR 676634-32-
```

5/RN OR 676634-33-6/RN OR 676634-34-7/RN OR 676634-35-8/RN OR 676634-36-9/RN OR 676634-37-0/RN OR 676634-38-1/RN OR 676634-39-2/RN OR 676634-40-5/RN OR 676634-41-6/RN OR 676634-42-7/RN OR 676634-43-8/RN OR 676634-44-9/RN OR 676634-45-0/RN OR 676634-46-1/RN OR 676634-47-2/RN OR 676634-48-3/RN OR 676634-49-4/RN OR 676634-50-7/RN OR 676634-51-8/RN OR 676634-52-9/RN OR 676634-53-0/RN OR 676634-54-1/RN OR 676634-55-2/RN OR 676634-56-3/RN OR 676634-57-4/RN OR 676634-58-5/RN OR 676634-59-6/RN OR 676634-60-9/RN OR 676634-61-0/RN OR 676634-62-1/RN OR 676634-63-2/RN OR 676634-64-3/RN OR 676634-65-4/RN OR 676634-66-5/RN OR 676634-67-6/RN OR 676634-68-7/RN OR 676634-69-8/RN OR 676634-70-1/RN OR 676634-71-2/RN OR 676634-72-3/RN OR 676634-73-4/RN OR 676634-74-5/RN OR 676634-75-6/RN)

L16 14 SEA FILE=REGISTRY ABB=ON PLU=ON L15 AND "L()VALINAMIDE"

L20 58 SEA FILE=REGISTRY ABB=ON PLU=ON (676634-77-8/RN OR 676634-78-9/RN OR 676634-79-0/RN OR 676634-80-3/RN OR 676634-81-4/RN OR 676634-82-5/RN OR 676634-83-6/RN OR 676634-84-7/RN OR 676634-85-8/RN OR 676634-86-9/RN OR 676634-87-0/RN OR 676634-88-1/RN OR 676634-89-2/RN OR 676634-90-5/RN OR 676634-91-6/RN OR 676634-92-7/RN OR 676634-93-8/RN OR 676634-94-9/RN OR 676634-95-0/RN OR 676634-96-1/RN OR 676634-97-2/RN OR 676634-98-3/RN OR 676634-99-4/RN OR 676635-00-0/RN OR 676635-01-1/RN OR 676635-02-2/RN OR 676635-03-3/RN OR 676635-04-4/RN OR 676635-05-5/RN OR 676635-06-6/RN OR 676635-07-7/RN OR 676635-08-8/RN OR 676635-09-9/RN OR 676635-10-2/RN OR 676635-11-3/RN OR 676635-12-4/RN OR 676635-13-5/RN OR 676635-14-6/RN OR 676635-15-7/RN OR 676635-16-8/RN OR 676635-17-9/RN OR 676635-18-0/RN OR 676635-19-1/RN OR 676635-20-4/RN OR 676635-21-5/RN OR 676635-22-6/RN OR 676635-23-7/RN OR 676635-24-8/RN OR 676635-25-9/RN OR 676635-26-0/RN OR 676635-27-1/RN OR 676635-28-2/RN OR 676635-29-3/RN OR 676635-30-6/RN OR 676635-31-7/RN OR 676635-32-8/RN OR 676635-33-9/RN OR 676635-34-0/RN)

L21 25 SEA FILE=REGISTRY ABB=ON PLU=ON L20 AND "L()VALINAMIDE"

L22 67 SEA FILE=REGISTRY ABB=ON PLU=ON (676635-33-9/RN OR 676635-34-0/RN OR 676635-35-1/RN OR 676635-36-2/RN OR 676635-37-3/RN OR 676635-38-4/RN OR 676635-39-5/RN OR 676635-40-8/RN OR 676635-41-9/RN OR 676635-42-0/RN OR 676635-43-1/RN OR 676635-44-2/RN OR 676635-45-3/RN OR 676635-46-4/RN OR 676635-47-5/RN OR 676635-48-6/RN OR 676635-49-7/RN OR 676635-50-0/RN OR 676635-51-1/RN OR 676635-52-2/RN OR 676635-53-3/RN OR 676635-54-4/RN OR 676635-55-5/RN OR 676635-56-6/RN OR 676635-57-7/RN OR 676635-58-8/RN OR 676635-59-9/RN OR 676635-60-2/RN OR 676635-61-3/RN OR 676635-62-4/RN OR 676635-63-5/RN OR 676635-64-6/RN OR 676635-65-7/RN OR 676635-66-8/RN OR 676635-67-9/RN OR 676635-68-0/RN OR 676635-69-1/RN OR 676635-70-4/RN OR 676635-71-5/RN OR 676635-72-6/RN OR 676635-73-7/RN OR 676635-74-8/RN OR 676635-75-9/RN OR 676635-76-0/RN OR 676635-77-1/RN OR 676635-78-2/RN OR 676635-79-3/RN OR 676635-80-6/RN OR 676635-81-7/RN OR 676635-82-8/RN OR 676635-83-9/RN OR 676635-84-0/RN OR 676635-85-1/RN OR 676635-86-2/RN OR 676635-87-3/RN OR 676635-88-4/RN OR 676635-89-5/RN OR 676635-90-8/RN OR 676635-91-9/RN OR 676635-92-0/RN OR 676635-93-1/RN OR 676635-94-2/RN OR 676635-95-3/RN OR 676635-96-4/RN OR 676635-97-5/RN OR 676635-98-6/RN OR 676635-99-7/RN)

L23 21 SEA FILE=REGISTRY ABB=ON PLU=ON L22 AND "L()VALINAMIDE"

L25 1 SEA FILE=REGISTRY ABB=ON PLU=ON L22 AND LEUCINAMIDE

L27 27 SEA FILE=REGISTRY ABB=ON PLU=ON (676636-02-5/RN OR 676636-03-6/RN OR 676636-04-7/RN OR 676636-05-8/RN OR 676636-06-9/RN OR 676636-07-0/RN OR 676636-08-1/RN OR 676636-09-2/RN OR 676636-10-5/RN OR 676636-11-6/RN OR 676636-12-7/RN OR 676636-13-8/RN OR 676636-14-9/RN OR 676636-15-0/RN OR 676636-16-1/RN OR 676636-17

-2/RN OR 676636-18-3/RN OR 676636-19-4/RN OR 676636-20-7/RN OR 676636-21-8/RN OR 676636-22-9/RN OR 676636-23-0/RN OR 676636-24-1/RN OR 676636-25-2/RN OR 676636-26-3/RN OR 676636-27-4/RN OR 676636-28-5/RN)

L28 14 SEA FILE=REGISTRY ABB=ON PLU=ON L27 AND "L()VALINAMIDE"

L29 22 SEA FILE=REGISTRY ABB=ON PLU=ON (676636-77-4/RN OR 676636-78-5/RN OR 676636-79-6/RN OR 676636-80-9/RN OR 676636-81-0/RN OR 676636-82-1/RN OR 676636-83-2/RN OR 676636-84-3/RN OR 676636-85-4/RN OR 676636-86-5/RN OR 676636-87-6/RN OR 676636-88-7/RN OR 676636-89-8/RN OR 676636-90-1/RN OR 676636-91-2/RN OR 676636-92-3/RN OR 676636-93-4/RN OR 676636-94-5/RN OR 676636-95-6/RN OR 676636-96-7/RN OR 676636-97-8/RN OR 676636-98-9/RN)

L30 4 SEA FILE=REGISTRY ABB=ON PLU=ON L29 AND "L()VALINAMIDE"

L31 29 SEA FILE=REGISTRY ABB=ON PLU=ON (676637-00-6/RN OR 676637-01-7/RN OR 676637-02-8/RN OR 676637-03-9/RN OR 676637-04-0/RN OR 676637-05-1/RN OR 676637-06-2/RN OR 676637-07-3/RN OR 676637-08-4/RN OR 676637-09-5/RN OR 676637-10-8/RN OR 676637-11-9/RN OR 676637-12-0/RN OR 676637-13-1/RN OR 676637-14-2/RN OR 676637-15-3/RN OR 676637-16-4/RN OR 676637-17-5/RN OR 676637-18-6/RN OR 676637-19-7/RN OR 676637-20-0/RN OR 676637-21-1/RN OR 676637-22-2/RN OR 676637-23-3/RN OR 676637-24-4/RN OR 676637-25-5/RN OR 676637-26-6/RN OR 676637-27-7/RN OR 676637-28-8/RN)

L32 8 SEA FILE=REGISTRY ABB=ON PLU=ON L31 AND "L()VALINAMIDE"

L33 70 SEA FILE=REGISTRY ABB=ON PLU=ON (676631-37-1/RN OR 676631-38-2/RN OR 676631-39-3/RN OR 676631-40-6/RN OR 676631-41-7/RN OR 676631-42-8/RN OR 676631-43-9/RN OR 676631-44-0/RN OR 676631-45-1/RN OR 676631-46-2/RN OR 676631-47-3/RN OR 676631-48-4/RN OR 676631-49-5/RN OR 676631-50-8/RN OR 676631-51-9/RN OR 676631-52-0/RN OR 676631-53-1/RN OR 676631-54-2/RN OR 676631-55-3/RN OR 676631-56-4/RN OR 676631-57-5/RN OR 676631-58-6/RN OR 676631-59-7/RN OR 676631-60-0/RN OR 676631-61-1/RN OR 676631-62-2/RN OR 676631-63-3/RN OR 676631-64-4/RN OR 676631-65-5/RN OR 676631-66-6/RN OR 676631-67-7/RN OR 676631-68-8/RN OR 676631-69-9/RN OR 676631-70-2/RN OR 676631-71-3/RN OR 676631-72-4/RN OR 676631-73-5/RN OR 676631-74-6/RN OR 676631-75-7/RN OR 676631-76-8/RN OR 676631-77-9/RN OR 676631-78-0/RN OR 676631-79-1/RN OR 676631-80-4/RN OR 676631-81-5/RN OR 676631-82-6/RN OR 676631-83-7/RN OR 676631-84-8/RN OR 676631-85-9/RN OR 676631-86-0/RN OR 676631-87-1/RN OR 676631-88-2/RN OR 676631-89-3/RN OR 676631-90-6/RN OR 676631-91-7/RN OR 676631-92-8/RN OR 676631-93-9/RN OR 676631-94-0/RN OR 676631-95-1/RN OR 676631-96-2/RN OR 676631-97-3/RN OR 676631-98-4/RN OR 676631-99-5/RN OR 676632-00-1/RN OR 676632-01-2/RN OR 676632-02-3/RN OR 676632-03-4/RN OR 676632-04-5/RN OR 676632-05-6/RN OR 676632-06-7/RN)

L34 30 SEA FILE=REGISTRY ABB=ON PLU=ON L33 AND "L()VALINAMIDE"

L35 108 SEA FILE=REGISTRY ABB=ON PLU=ON (676632-05-6/RN OR 676632-06-7/RN OR 676632-07-8/RN OR 676632-08-9/RN OR 676632-09-0/RN OR 676632-10-3/RN OR 676632-11-4/RN OR 676632-12-5/RN OR 676632-13-6/RN OR 676632-14-7/RN OR 676632-15-8/RN OR 676632-16-9/RN OR 676632-17-0/RN OR 676632-18-1/RN OR 676632-19-2/RN OR 676632-20-5/RN OR 676632-21-6/RN OR 676632-22-7/RN OR 676632-23-8/RN OR 676632-24-9/RN OR 676632-25-0/RN OR 676632-26-1/RN OR 676632-27-2/RN OR 676632-28-3/RN OR 676632-29-4/RN OR 676632-30-7/RN OR 676632-31-8/RN OR 676632-32-9/RN OR 676632-33-0/RN OR 676632-34-1/RN OR 676632-35-2/RN OR 676632-36-3/RN OR 676632-37-4/RN OR 676632-38-5/RN OR 676632-39-6/RN OR 676632-40-9/RN OR 676632-41-0/RN OR 676632-42-1/RN OR 676632-43-2/RN OR 676632-44-3/RN OR 676632-45-4/RN OR 676632-46-5/RN OR 676632-47-6/RN OR 676632-48-7/RN OR 676632-49-8/RN OR 676632-50-1/RN OR 676632-51-2/RN OR 676632-52-3/RN OR 676632-53-4/RN OR 676632-54-5/RN OR 676632-55

-6/RN OR 676632-56-7/RN OR 676632-57-8/RN OR 676632-58-9/RN OR
676632-59-0/RN OR 676632-60-3/RN OR 676632-61-4/RN OR 676632-62
-5/RN OR 676632-63-6/RN OR 676632-64-7/RN OR 676632-65-8/RN OR
676632-66-9/RN OR 676632-67-0/RN OR 676632-68-1/RN OR 676632-69
-2/RN OR 676632-70-5/RN OR 676632-71-6/RN OR 676632-72-7/RN OR
676632-73-8/RN OR 676632-74-9/RN OR 676632-75-0/RN OR 676632-76
-1/RN OR 676632-77-2/RN OR 676632-78-3/RN OR 676632-79-4/RN OR
676632-80-7/RN OR 676632-81-8/RN OR 676632-82-9/RN OR 676632-83
-0/RN OR 676632-84-1/RN OR 676632-85-2/RN OR 676632-86-3/RN OR
676632-87-4/RN OR 676632-88-5/RN OR 676632-89-6/RN OR 676632-90
-9/RN OR 676632-91-0/RN OR 676632-92-1/RN OR 676632-93-2/RN OR
676632-94-3/RN OR 676632-95-4/RN OR 676632-96-5/RN OR 676632-97
-6/RN OR 676632-98-7/RN OR 676632-99-8/RN OR 676633-00-4/RN OR
676633-01-5/RN OR 676633-02-6/RN OR 676633-03-7/RN OR 676633-04
-8/RN OR 676633-05-9/RN OR 676633-06-0/RN OR 676633-07-1/RN OR
676633-08-2/RN OR 676633-09-3/RN OR 676633-10-6/RN OR 676633-11
-7/RN OR 676633-12-8/RN)

```
L36          48 SEA FILE=REGISTRY ABB=ON  PLU=ON  L35 AND "L()VALINAMIDE"
L45         209 SEA FILE=REGISTRY ABB=ON  PLU=ON  L3 OR L5 OR L7 OR L10 OR L14
                OR L16 OR L21 OR L23 OR L25 OR L28 OR L30 OR L32 OR L34 OR L36
L46          11 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L45
L51           8 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L46 AND (CANCER? OR NEOPLAS?
                OR TUMOR? OR TUMOUR? OR CARCIN?)
L54      168148 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (TUMORS/CT OR NEOPLASM/CT)
L55           7 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L46 AND L54
L56           8 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L51 OR L55


=> d 156 1-8 ibib abs hitstr hitind

L56  ANSWER 1 OF 8  HCAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2006:1140680  HCAPLUS  Full-text
DOCUMENT NUMBER:          146:59167
TITLE:                    A missense mutation in Caenorhabditis elegans
                          prohibitin 2 confers an atypical multidrug resistance
AUTHOR(S):                Zubovych, Iryna; Doundoulakis, Thomas; Harran, Patrick
                          G.; Roth, Michael G.
CORPORATE SOURCE:         Dep. Biochem., Univ. Texas Southwestern Med. Cent.,
                          Dallas, TX, 75390-9038, USA
SOURCE:                   Proceedings of the National Academy of Sciences of the
                          United States of America (2006), 103(42), 15523-15528
                          CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER:                National Academy of Sciences
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
AB   Hemiasterlin is a potent antimitotic peptide that interferes with microtubule
     dynamics at picomolar concns. in cell culture.  The mol. largely eludes P
     glycoprotein-mediated drug efflux, and an analog is currently being evaluated
     in clin. trials as cancer chemotherapy.  From a nonclonal genetic screen in
     Caenorhabditis elegans we isolated eight independent mutants resistant to a
     synthetic hemiasterlin analog.  In one recessive mutant, phb2(ad2154), a point
     mutation in prohibitin 2 (E130K) protects worms from drug-induced injury. Data
     indicate that direct binding of hemiasterlin to prohibitin 2 is unlikely.  In
     fact, C. elegans phb2(ad2154) was also found to be resistant to numerous other
     drugs that bind tubulin and to camptothecin, yet this mutant was sensitive to
     nocodazole and phalloidin.  Thus, prohibitin 2 is implicated in a previously
     uncharacterized pathway of multidrug resistance.
IT   676632-55-6
     RL: BSU (Biological study, unclassified); BUU (Biological use,
     unclassified); BIOL (Biological study); USES (Uses)
```

(missense mutation in Caenorhabditis elegans prohibitin 2 confers an atypical multidrug resistance)

RN 676632-55-6 HCAPLUS

CN L-Valinamide, 3-bromo-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-buten-1-yl]-N,3-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



CC 12-4 (Nonmammalian Biochemistry)
Section cross-reference(s): 3

IT 17466-45-4, Phalloidin 31430-18-9, Nocodazole 157207-90-4, Hemiasterlin 228266-40-8, HTI 286 676632-55-6 916980-93-3 916980-94-4
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(missense mutation in Caenorhabditis elegans prohibitin 2 confers an atypical multidrug resistance)

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:140787 HCAPLUS Full-text
DOCUMENT NUMBER: 142:240718
TITLE: Preparation of peptides for treating tumors
INVENTOR(S): Zask, Arie; Kaplan, Joshua; Yamashita, Ayako; Niu, Chuan S.; Birnberg, Gary Harold; Norton, Emily; Cheung, Kinwang; Suayan, Ronald; Sandanayaka, Vincent; Hamann, Philip Ross; Ayral-Kaloustian, Semiramis
PATENT ASSIGNEE(S): Wyeth Holdings Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 64 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050037977	A1	20050217	US 2004-911300	20040804
US 7390910	B2	20080624		
WO 2005016958	A2	20050224	WO 2004-US25246	20040805
WO 2005016958	A3	20050602		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20080221181 A1 20080911 US 2008-104921 20080417
PRIORITY APPLN. INFO.: US 2003-493841P P 20030808
US 2004-911300 A3 20040804

OTHER SOURCE(S): CASREACT 142:240718; MARPAT 142:240718

AB The invention provides peptides A-CH(E)C(:B')NR6CHR7CONR8R9 [A is (un)substituted alkyl, alkenyl, aryl or cyclic hydrocarbyl or aza/oxa/thia analogs; B' is O or H2; E is (un)substituted alkyl, aryl, cyclic hydrocarbyl, etc.; R6-R8 are H or groups defined by A; R9 is an alkyl group which is substituted by sulfonyl, phosphoryl, acyl, hydroxyalkyl, etc.] which exhibit anticancer activity. Thus, N,β,β,3-tetramethyl-L-phenylalanyl-N1-[(1S,2E)-1-isopropyl-3- methyl-4-morpholino-4-oxobut-2-enyl]-N1,3-dimethyl-L-valinamide was prepared and showed IC50 values 19.5, 56 and 1514 nM against KB, KB85 and KBV1 cell lines and 79% inhibition of tubulin polymerization at 0.3 μN.

IT 676631-65-5 676631-81-5 676631-97-3
676632-00-1 676632-05-6 676632-08-9
676633-60-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of peptides for treating tumors)

RN 676631-65-5 HCAPLUS

CN L-Valinamide, 3-chloro-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-81-5 HCAPLUS

CN L-Valinamide, N,β,β,3-tetramethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-97-3 HCAPLUS
CN L-Valinamide, N,β,β,3,4-pentamethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-00-1 HCAPLUS
CN L-Valinamide, N,β,β,3,4-pentamethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-05-6 HCAPLUS
CN L-Valinamide, N,β,β,3,5-pentamethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-08-9 HCAPLUS
CN L-Valinamide, N,β,β,3,5-pentamethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-60-6 HCAPLUS
CN L-Valinamide, 3-cyclohexyl-N-methyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IC ICM A61K038-04
ICS A61K031-277
INCL 514019000; 514513000; 514528000; 514616000; 558410000; 558254000; 564152000; 564154000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1
IT Structure-activity relationship
(antitumor; preparation of peptides for treating tumors)
IT Antitumor agents
Neoplasm
(preparation of peptides for treating tumors)
IT Peptides, preparation
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of peptides for treating tumors)
IT 610786-89-5P 755757-89-2P 755757-90-5P 755757-92-7P 755758-05-5P
845291-97-6P 845291-99-8P 845292-00-4P 845292-07-1P 845292-15-1P
845292-17-3P 845292-20-8P 845292-23-1P 845292-32-2P 845292-33-3P
845292-35-5P 845292-36-6P 845292-37-7P 845292-38-8P 845292-39-9P

845292-60-6P 845292-62-8P 845292-64-0P 845292-66-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of peptides for treating tumors)

IT 228266-40-8P 610786-90-8P 610787-28-5P 755757-91-6P 755757-93-8P
755757-94-9P 755757-95-0P 755757-96-1P 755757-97-2P 755757-98-3P
755757-99-4P 755758-00-0P 755758-01-1P 755758-02-2P 755758-03-3P
755758-04-4P 755758-06-6P 755758-07-7P 755758-08-8P 755758-09-9P
755758-10-2P 755758-11-3P 755758-12-4P 755758-13-5P 755758-21-5P
765930-76-5P 765930-77-6P 765930-81-2P 765930-82-3P 765931-54-2P
765931-56-4P 765931-58-6P 765931-60-0P 765931-62-2P 765931-64-4P
765931-66-6P 765931-70-2P 765931-91-7P 765931-93-9P 765931-94-0P
765931-96-2P 765931-99-5P 765932-02-3P 765932-03-4P 845291-77-2P
845291-78-3P 845291-79-4P 845291-80-7P 845291-81-8P 845291-82-9P
845291-83-0P 845291-84-1P 845291-85-2P 845291-86-3P 845291-87-4P
845291-88-5P 845291-89-6P 845291-90-9P 845291-91-0P 845291-92-1P
845291-93-2P 845291-94-3P 845291-95-4P 845291-96-5P 845291-98-7P
845292-01-5P 845292-03-7P 845292-04-8P 845292-05-9P 845292-06-0P
845292-08-2P 845292-09-3P 845292-10-6P 845292-11-7P 845292-12-8P
845292-13-9P 845292-14-0P 845292-16-2P 845292-18-4P 845292-19-5P
845292-21-9P 845292-22-0P 845292-24-2P 845292-25-3P 845292-26-4P
845292-28-6P 845292-29-7P 845292-30-0P 845292-31-1P 845292-34-4P
845292-40-2P 845292-41-3P 845292-42-4P 845292-43-5P 845292-44-6P
845292-45-7P 845292-46-8P 845292-47-9P 845292-48-0P 845292-49-1P
845292-50-4P 845292-51-5P 845292-52-6P 845292-53-7P 845292-54-8P
845292-55-9P 845292-56-0P 845292-57-1P 845292-58-2P 845292-59-3P
845292-61-7P 845292-63-9P 845292-65-1P 845292-67-3P 845292-68-4P
845292-69-5P 845292-70-8P 845292-71-9P 845292-72-0P 845292-74-2P
845292-75-3P 845292-76-4P 845292-77-5P 845292-78-6P 845292-79-7P
845292-80-0P 845292-81-1P 845292-82-2P 845292-83-3P 845292-84-4P
845292-85-5P 845292-86-6P 845292-87-7P 845292-88-8P 845292-89-9P
845292-90-2P 845292-91-3P 845292-92-4P 845292-93-5P 845292-94-6P
845292-95-7P 845292-96-8P 845292-97-9P 845292-98-0P 845292-99-1P
845293-00-7P 845293-01-8P 845293-02-9P 845293-03-0P 873530-02-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides for treating tumors)

IT 64-04-0, Phenethylamine 100-58-3, Phenylmagnesium bromide 103-82-2, Benzeneacetic acid, reactions 106-93-4, 1 2 Dibromoethane 109-01-3, 1 Methylpiperazine 110-91-8, Morpholine, reactions 156-06-9, 3-Phenyl 2 oxopropanoic acid 288-47-1, Thiazole 475-11-6, n Methyl L-proline 515-40-2, Neophyl chloride 529-34-0, α-Tetralone 556-56-9, Allyl iodide 616-04-6, 1-Methylhydantoin 624-92-0, Dimethyldisulfide 712-76-5, 4-Phenylbenzylamine 836-43-1, 4 Benzyloxy benzyl alcohol 877-96-3 1779-28-8 2133-40-6 2280-27-5 2759-28-6, 1 Benzylpiperazine 2942-58-7, Diethyl cyanophosphonate 2999-46-4, Ethyl isocyanoacetate 3034-53-5, 2 Bromothiazole 5717-37-3, Carbethoxyethylidene triphenylphosphorane 15761-39-4 16001-93-7, Tetramethyl methylenediphosphonate 16640-68-9, Triphenylphosphoranylidene acetonitrile 17016-83-0, s 4 Isopropyl 2 oxazolidinone 18650-39-0 36982-84-0, Trisyl azide 40216-83-9 45170-31-8 51154-06-4 62965-35-9 65365-28-8 68641-49-6, Bis(2-oxo-3-oxazolidinyl)phosphinic chloride 69610-41-9, Boc prolinal 73300-75-1 77877-20-4 82650-30-4 90719-32-7 95378-36-2 138802-17-2 150019-50-4 165534-43-0, Depbt 169870-82-0 184434-17-1 187345-38-6 228266-38-4 500229-47-0 610786-70-4 676631-65-5 676631-81-5 676631-97-3 676632-00-1 676632-05-6 676632-08-9 676633-60-6

765932-28-3 845293-04-1 845293-06-3 845293-09-6 845293-36-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of peptides for treating tumors)
IT 1010-48-6P 67319-04-4P, 1-Ethoxymethyl-1H-imidazole 74641-60-4P, n Methylphenylglycine 74844-93-2P 77586-77-7P 77586-78-8P 91133-59-4P 92235-33-1P 95092-10-7P 109133-93-9P 120205-50-7P 120205-54-1P 130199-65-4P, 2 Thiazolemethanamine, α phenylmethyl, s 133120-91-9P 133565-38-5P 133645-51-9P 140670-72-0P 144774-99-2P 144775-06-4P 144831-03-8P, 2 Thiazolemethanol, α phenylmethyl, r 149606-89-3P 159525-39-0P 169768-92-7P 169768-95-0P 179039-97-5P 180715-99-5P 182573-17-7P 186145-08-4P 228266-34-0P 676629-67-7P 765930-74-3P 765930-79-8P 765930-91-4P 765930-93-6P 765930-95-8P 765930-98-1P 765931-01-9P 765932-15-8P 765932-18-1P 765932-20-5P 765932-22-7P 765932-24-9P 845293-07-4P 845293-10-9P 845293-11-0P 845293-12-1P 845293-13-2P 845293-14-3P 845293-15-4P 845293-16-5P 845293-17-6P 845293-18-7P 845293-19-8P 845293-20-1P 845293-21-2P 845293-22-3P 845293-23-4P 845293-24-5P 845293-27-8P 845293-29-0P 845293-30-3P 845293-31-4P 845293-32-5P 845293-33-6P 845293-34-7P 845293-35-8P 845293-37-0P 845293-38-1P 845293-39-2P 845293-40-5P 845293-41-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of peptides for treating tumors)
IT 765931-16-6P 765932-37-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of peptides for treating tumors)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:617803 HCAPLUS Full-text
DOCUMENT NUMBER: 141:314607
TITLE: Synthesis and Biological Activity of Analogues of the Antimicrotubule Agent N,β,β-Trimethyl-L-phenylalanyl-N1-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]-N1,3-dimethyl-L-valinamide (HTI-286)
AUTHOR(S): Zask, Arie; Birnberg, Gary; Cheung, Katherine; Kaplan, Joshua; Niu, Chuan; Norton, Emily; Suayan, Ronald; Yamashita, Ayako; Cole, Derek; Tang, Zhilian; Krishnamurthy, Girija; Williamson, Robert; Khafizova, Gulnaz; Musto, Sylvia; Hernandez, Richard; Annable, Tami; Yang, Xiaoran; Discafani, Carolyn; Beyer, Carl; Greenberger, Lee M.; Loganzo, Frank; Ayral-Kaloustian, Semiramis
CORPORATE SOURCE: Chemical and Screening Sciences, and Oncology Research, Wyeth Research, Pearl River, NY, 10965, USA
SOURCE: Journal of Medicinal Chemistry (2004), 47(19), 4774-4786
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:314607
GI



I

AB Hemiasterlin, a tripeptide isolated from marine sponges, induces microtubule depolymn. and mitotic arrest in cells. HTI-286, an analog from an initial study of the hemiasterlins, is presently in clin. trials. In addition to its potent antitumor effects, HTI-286 has the advantage of circumventing the P-glycoprotein-mediated resistance that hampers the efficacy of other antimicrotubule agents such as paclitaxel and vincristine in animal models. This paper describes an in-depth study of the structure-activity relationships (SAR) of analogs of HTI-286, their effects on microtubule polymerization, and their in vitro and in vivo anticancer activity. Regions of the mol. necessary for potent activity are identified. Groups tolerant of modification, leading to novel analogs, are reported. Potent analogs identified through in vivo studies in tumor xenograft models include one superior analog, HTI-042 (I).

IT 676633-19-5P 676633-61-7P 676633-65-1P
676633-80-0P 676633-90-2P 676634-47-2P
676634-83-6P 676634-90-5P 676634-93-8P
676635-36-2P 676635-39-5P 676635-58-8P
676636-07-0P 676636-15-0P 676636-19-4P
676636-28-5P 676636-79-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of analogs of peptide HTI-286 and SAR study of their anticancer
activity and effects on microtubule polymerization)

RN 676633-19-5 HCAPLUS

CN L-Valinamide, N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-18-4
CMF C28 H45 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676633-61-7 HCAPLUS
CN L-Valinamide, 3-cyclohexyl-N-methyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-60-6
CMF C27 H49 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676633-65-1 HCAPLUS
CN L-Valinamide, (2S)-N-methyl-2-(1-phenylcyclopentyl)glycyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-64-0
CMF C29 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676633-80-0 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S)-1-[(1E)-2-carboxy-1-propenyl]pentyl]-N,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 676633-90-2 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-pentenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-89-9
CMF C28 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676634-47-2 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-ethyl-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676634-83-6 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676634-90-5 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-amino-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676634-89-2
CMF C27 H44 N4 O3

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676634-93-8 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N,3-dimethyl-N-[(1S,2E)-3-methyl-4-(methylamino)-1-(1-methylethyl)-4-oxo-2-butenyl]-,

mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676634-92-7
CMF C28 H46 N4 O3

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676635-36-2 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1R,3S)-3-carboxy-1-(1-methylethyl)butyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676635-35-1
CMF C27 H45 N3 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676635-39-5 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1R,3R)-3-carboxy-1-(1-methylethyl)butyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676635-38-4
CMF C27 H45 N3 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676635-58-8 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(phenylmethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676636-07-0 HCAPLUS

CN L-Valinamide, N-ethyl-β,β-dimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676636-06-9
CMF C28 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676636-15-0 HCAPLUS

CN L-Valinamide, N-(2-hydroxyethyl)-β,β-dimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 676636-14-9
CMF C28 H45 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676636-19-4 HCAPLUS

CN L-Valinamide, (βR)-N,β-dimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676636-18-3
CMF C26 H41 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676636-28-5 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1R,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676636-27-4
CMF C27 H43 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676636-79-6 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl-3-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1

IT Antitumor agents
Human
Neoplasm
(preparation of analogs of peptide HTI-286 and SAR study of their anticancer
activity and effects on microtubule polymerization)

IT 228266-43-1P 228266-45-3P 228266-48-6P 676633-19-5P
676633-61-7P 676633-65-1P 676633-77-5P
676633-80-0P 676633-90-2P 676634-21-2P
676634-47-2P 676634-59-6P 676634-66-5P 676634-77-8P
676634-83-6P 676634-90-5P 676634-93-8P
676635-36-2P 676635-39-5P 676635-58-8P
676636-07-0P 676636-11-6P 676636-15-0P
676636-19-4P 676636-28-5P 676636-79-6P
765930-77-6P 765930-82-3P 765930-86-7P 765930-88-9P 765931-06-4P
765931-11-1P 765931-16-6P 765931-18-8P 765931-22-4P 765931-24-6P
765931-27-9P 765931-29-1P 765931-33-7P 765931-35-9P 765931-39-3P
765931-44-0P 765931-47-3P 765931-49-5P 765931-52-0P 765931-54-2P
765931-56-4P 765931-58-6P 765931-60-0P 765931-62-2P 765931-64-4P
765931-67-7P 765931-71-3P 765931-73-5P 765931-89-3P 765931-91-7P
765931-94-0P 765931-97-3P 765932-00-1P 765932-03-4P 765932-05-6P
765932-08-9P 765932-10-3P 765932-35-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of analogs of peptide HTI-286 and SAR study of their anticancer
activity and effects on microtubule polymerization)

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:581062 HCAPLUS Full-text
DOCUMENT NUMBER: 141:253658
TITLE: D-piece modifications of the hemiasterlin analog HTI-286 produce potent tubulin inhibitors
AUTHOR(S): Zask, Arie; Birnberg, Gary; Cheung, Katherine; Kaplan, Joshua; Niu, Chuan; Norton, Emily; Yamashita, Ayako; Beyer, Carl; Krishnamurthy, Girija; Greenberger, Lee M.; Loganzo, Frank; Ayral-Kaloustian, Semiramis
CORPORATE SOURCE: Chemical and Screening Sciences, Wyeth Research, Pearl River, NY, 10965, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(16), 4353-4358
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:253658
GI



I

AB Modifications of the D-piece carboxylic acid group of the hemiasterlin analog HTI-286 gave tubulin inhibitors which were potent cytotoxic agents in taxol resistant cell lines expressing P-glycoprotein. Amides derived from proline had potency comparable to HTI-286. Reduction of the carboxylic acid to ketones and alcs. or its conversion to acidic heterocycles also gave potent analogs. Synthetic modifications of the carboxylic acid could be carried out selectively using a wide range of synthetic reagents. Proline analog (I) was effective in a human xenograft model in athymic mice.

IT 676631-65-5 676631-81-5 676631-97-3
676633-60-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(D-piece modifications of the hemiasterlin analog HTI-286 produce potent tubulin inhibitors)

RN 676631-65-5 HCAPLUS

CN L-Valinamide, 3-chloro-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-81-5 HCAPLUS
CN L-Valinamide, N,β,β,3-tetramethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-97-3 HCAPLUS
CN L-Valinamide, N,β,β,3,4-pentamethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-60-6 HCAPLUS
CN L-Valinamide, 3-cyclohexyl-N-methyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



CC 1-3 (Pharmacology)
Section cross-reference(s): 25
IT Antitumor agents
Human
Neoplasm
Structure-activity relationship
(D-piece modifications of the hemiasterlin analog HTI-286 produce potent tubulin inhibitors)
IT 64-04-0, Benzeneethanamine 100-58-3 1099-45-2 1499-56-5 2577-48-2 5717-37-3 16640-68-9 33973-48-7 40610-14-8 43041-12-9 45170-31-8 90710-04-6, 2-Piperidinecarboxylic acid, methyl ester, (s)- 95378-36-2 107905-52-2 109133-93-9 138802-17-2 210420-92-1 371252-56-1 552331-26-7 676631-65-5 676631-81-5 676631-97-3 676633-60-6 845293-38-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(D-piece modifications of the hemiasterlin analog HTI-286 produce potent tubulin inhibitors)
REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:581057 HCAPLUS Full-text
DOCUMENT NUMBER: 141:277875
TITLE: Tubulin inhibitors. Synthesis and biological activity of HTI-286 analogs with B-segment heterosubstituents
AUTHOR(S): Niu, Chuan; Smith, Daniel; Zask, Arie; Loganzo, Frank; Discafani, Carolyn; Beyer, Carl; Greenberger, Lee; Ayral-Kaloustian, Semiramis
CORPORATE SOURCE: Chemical and Screening Sciences, Discovery Medicinal Chemistry, Wyeth Research, Pearl River, NY, 10965, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(16), 4329-4332
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:277875
GI



I



II

AB Modifications of the B-segment of HTI-286 (I) produced a class of analogs, peptides II [R1 = Me, H; R2 = SMe, S(:O)Me, SO2Me, SCH2C6H4OMe-4, C6H4OMe-4, OH, OMe; R3 = H, OMe] containing heteroatom-substituents. Majority of II strongly inhibited tubulin polymerization, and structure-activity relationship of II towards tubulin polymerization was evaluated. In addition, in vivo assays of II (R1 = Me, R2 = SMe, R3 = H; R1 = Me, R2 = SMe, R3 = OMe) revealed that these two compds. effectively inhibited the growth of human tumor xenografts in athymic mice, including tumors resistant to paclitaxel.

IT 676633-99-1P 676634-06-3P 676634-10-9P
676635-98-6P 676636-24-1P 676636-79-6P
676636-82-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and biol. activity of heteroatom-substituted HTI-286 peptide analogs as inhibitors of tubulin polymerization and as potent antitumor agents)

RN 676633-99-1 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676634-06-3 HCAPLUS

CN L-Valinamide, N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-[[(4-methoxyphenyl)methyl]thio]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676634-10-9 HCAPLUS
CN L-Valinamide, N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl-3-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676635-98-6 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-fluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676636-24-1 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-hydroxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676636-79-6 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl-3-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676636-82-1 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-[[(4-methoxyphenyl)methyl]thio]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1
IT Antitumor agents
Human
Melanoma
Neoplasm
(preparation and biol. activity of heteroatom-substituted HTI-286 peptide analogs as inhibitors of tubulin polymerization and as potent antitumor agents)
IT 676633-99-1P 676634-06-3P 676634-10-9P
676634-17-6P 676635-98-6P 676636-24-1P
676636-79-6P 676636-82-1P 676636-87-6P 757242-17-4P
757242-18-5P 757242-19-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and biol. activity of heteroatom-substituted HTI-286 peptide analogs as inhibitors of tubulin polymerization and as potent antitumor agents)
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:580770 HCAPLUS Full-text
DOCUMENT NUMBER: 141:253645
TITLE: Probing the Interaction of HTI-286 with Tubulin Using a Stilbene Analogue
AUTHOR(S): Lo, Mei-Chu; Aulabaugh, Ann; Krishnamurthy, Girija; Kaplan, Joshua; Zask, Arie; Smith, Robert P.; Ellestad, George
CORPORATE SOURCE: Biophysics/Enzymology-Chemical and Screening Sciences, Medicinal Chemistry-Chemical and Screening Sciences, and Vaccines Research, Wyeth Research, Pearl River, NY, 10965, USA
SOURCE: Journal of the American Chemical Society (2004), 126(32), 9898-9899
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:253645
AB HTI-286 is a synthetic analog of the natural product hemiasterlin. HTI-286 is a potent antitumor agent that induces tubulin oligomerization. To investigate the binding stoichiometry and the binding site during this ligand-induced tubulin association, synthesized an analog of HTI-286 containing the chromophore stilbene was synthesized. Using the distinct UV absorbance of the stilbene analog, the amts. of inhibitors bound to different tubulin oligomers was determined by anal. ultracentrifugation. Herein described are findings based on these expts. At the ratio of inhibitor to protein equal to or greater than 1, the stilbene analog induces oligomerization of tubulin to a ring structure. The binding stoichiometry in the ring is one inhibitor per tubulin monomer (defined as an α/β-heterodimer). At the ratio of inhibitor to protein less than 1, tubulin forms multiple intermediates, with the binding stoichiometry less than one inhibitor per tubulin monomer for all intermediates. The stable complex between the inhibitor and tubulin monomer was not detected under these exptl. conditions. The binding site of the stilbene analog does not overlap with the classic tubulin-binding agent, colchicine.
IT 676635-83-9

RL: PAC (Pharmacological activity); BIOL (Biological study)
(interaction of HTI-286 stilbene analog with tubulin)

RN 676635-83-9 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-4-[(1E)-2-phenylethenyl]-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 676635-84-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(interaction of HTI-286 stilbene analog with tubulin)

RN 676635-84-0 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-4-[(1E)-2-phenylethenyl]-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676635-83-9
CMF C35 H49 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

CC 1-3 (Pharmacology)
Section cross-reference(s): 34
IT Antitumor agents
Neoplasm
Stoichiometry
Structure-activity relationship
(interaction of HTI-286 stilbene analog with tubulin)
IT 676635-83-9
RL: PAC (Pharmacological activity); BIOL (Biological study)
(interaction of HTI-286 stilbene analog with tubulin)
IT 91133-59-4P 676627-53-5P 676627-58-0P 676635-84-0P
756894-40-3P 756894-42-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(interaction of HTI-286 stilbene analog with tubulin)
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:470934 HCAPLUS Full-text
DOCUMENT NUMBER: 141:47298
TITLE: Hemiasterlin affinity probes and their uses for identifying binding sites and/or targets for anticancer drugs
INVENTOR(S): Greenberger, Lee M.
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004047615	A2	20040610	WO 2003-US37393	20031121
WO 2004047615	A3	20040812		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003295808	A1	20040618	AU 2003-295808	20031121
US 20070026478	A1	20070201	US 2005-536262	20050520
PRIORITY APPLN. INFO.:			US 2002-428050P P	20021121
			WO 2003-US37393 W	20031121
OTHER SOURCE(S):	MARPAT 141:47298			

AB The invention relates to methods and compns. for identifying anticancer drugs and, in particular, for identifying binding sites and/or targets for anticancer drugs. Photoaffinity probes are provided that mimic the binding of hemiasterlin derivs., including the hemiasterlin derivative HTI-286, to tubulin. The invention also relates to methods for using such probes - including methods for identifying drug binding sites on tubulin, as well as diagnostic and prognostic methods that use these probes to identify cells containing mutant tubulin such as tumor cells. Addnl. it relates to methods using target binding sites that are identified with such probes; e.g., to identify new binding compds. and potential therapeutic compds., and/or to identify potentially drug resistant cells and tumors.

IT 676634-35-8P

RL: ARU (Analytical role, unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(hemiasterlin affinity probes and their uses for identifying binding sites and/or targets for anticancer drugs)

RN 676634-35-8 HCAPLUS

CN L-Valinamide, 4-benzoyl-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IC ICM A61B

CC 1-6 (Pharmacology)
Section cross-reference(s): 25

ST hemiasterlin affinity probe antitumor drug target cancer diagnosis

IT Diagnosis

(cancer; hemiasterlin affinity probes and their uses for identifying binding sites and/or targets for anticancer drugs)

IT Antitumor agents
Drug targets
Human
Neoplasm
Photoaffinity
Protein sequences
Rattus

(hemiasterlin affinity probes and their uses for identifying binding sites and/or targets for anticancer drugs)

IT 676634-31-4P 676634-35-8P

RL: ARU (Analytical role, unclassified); DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP

(Preparation); USES (Uses)
(hemiasterlin affinity probes and their uses for identifying binding sites and/or targets for anticancer drugs)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:267231 HCAPLUS Full-text
DOCUMENT NUMBER: 140:304081
TITLE: Preparation of peptides for treating resistant tumors
INVENTOR(S): Greenberger, Lee Martin; Loganzo, Frank, Jr.; Discafani-Marro, Carolyn Mary; Zask, Arie; Ayral-Kaloustian, Semiramis
PATENT ASSIGNEE(S): Wyeth Holdings Corporation, USA
SOURCE: PCT Int. Appl., 442 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026293	A2	20040401	WO 2003-US29832	20030918
WO 2004026293	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2406504	A1	20040320	CA 2002-2406504	20021003
AU 2003275126	A1	20040408	AU 2003-275126	20030918
US 20040121965	A1	20040624	US 2003-666722	20030918
PRIORITY APPLN. INFO.:			US 2002-411883P P	20020920
			WO 2003-US29832 W	20030918

OTHER SOURCE(S): MARPAT 140:304081
AB The invention provides peptides R1R2NCH(CR3R4R5)CONR6CHR7CONR8R9 [R1-R8 are H or an (un)saturated moiety having a linear, branched, or cyclic skeleton containing 1-10 (un)substituted carbon atoms and 0-4 each nitrogen, oxygen, or sulfur atoms; or R1R2N or R3R4C is a 3- to 7-membered ring; R9 is -Y-CO-Z, where Y is alkyl and Z is OH, SH, NH2, an amino acid residue, etc. (with provisos)] for treating or inhibiting the growth or eradication of tumors which are resistant to at least one chemotherapeutic agent. Thus, N,β,β-trimethyl-L-phenylalanyl-N1-[(1S,2E)-3-carboxy-1- isopropylbut-2-enyl]-N1,3-dimethyl-L-valinamide was prepared and shown to be a potent inhibitor of cell growth in 34 tumor cell lines (mean IC50 = 2.1 ± 1.7 nM, median 1.7 nM, range 0.2-7.3 nM) and is distinct from paclitaxel which has an usually large range of activity. The activity is independent of tumor origin and in many cases this peptide is considerably more potent than paclitaxel.
IT 676631-63-3P 676631-71-3P 676631-78-0P
676631-86-0P 676631-94-0P 676632-03-4P
676632-11-4P 676632-20-5P 676632-31-8P
676632-40-9P 676632-45-4P 676632-48-7P
676632-66-9P 676632-69-2P 676635-06-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of peptides for treating resistant tumors)

RN 676631-63-3 HCAPLUS

CN L-Valinamide, 3-chloro-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-71-3 HCAPLUS

CN L-Valinamide, 4-chloro-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-78-0 HCAPLUS

CN L-Valinamide, N,β,β,3-tetramethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-86-0 HCAPLUS
CN L-Valinamide, N,β,β,4-tetramethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-94-0 HCAPLUS
CN L-Valinamide, N,β,β,3,4-pentamethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-03-4 HCAPLUS
CN L-Valinamide, N,β,β,3,5-pentamethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-11-4 HCAPLUS
CN L-Valinamide, N-methyl-3-(2-thienyl)-L-valyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-20-5 HCAPLUS
CN L-Valinamide, N-methyl-3-(3-thienyl)-L-valyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-31-8 HCAPLUS
CN L-Valinamide, 3-benzo[b]thien-2-yl-N-methylvalyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-40-9 HCAPLUS

CN L-Valinamide, N-ethyl-β,β-dimethylphenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-45-4 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-N,β,β,2-tetramethylphenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-48-7 HCAPLUS

CN L-Valinamide, N,β,β,2-tetramethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-66-9 HCAPLUS
CN L-Valinamide, 3-[1,1'-biphenyl]-3-yl-N-methyl-D-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676632-65-8
CMF C33 H47 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676632-69-2 HCAPLUS
CN L-Valinamide, 3-ethenyl-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 676632-68-1
CMF C29 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676635-06-6 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-[[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]methylamino]-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 676631-37-1P 676631-40-6P 676631-42-8P
676631-44-0P 676631-47-3P 676631-50-8P
676631-52-0P 676631-55-3P 676631-57-5P
676631-60-0P 676631-61-1P 676631-65-5P
676631-68-8P 676631-74-6P 676631-76-8P
676631-81-5P 676631-84-8P 676631-88-2P
676631-89-3P 676631-91-7P 676631-92-8P
676631-97-3P 676632-00-1P 676632-05-6P
676632-08-9P 676632-14-7P 676632-17-0P
676632-22-7P 676632-25-0P 676632-28-3P

676632-33-0P 676632-38-5P 676632-42-1P
676632-51-2P 676632-53-4P 676632-55-6P
676632-56-7P 676632-58-9P 676632-59-0P
676632-61-4P 676632-62-5P 676632-65-8P
676632-68-1P 676632-71-6P 676632-72-7P
676632-75-0P 676632-76-1P 676632-78-3P
676632-79-4P 676632-82-9P 676632-83-0P
676632-86-3P 676632-87-4P 676632-90-9P
676632-91-0P 676632-94-3P 676632-97-6P
676632-99-8P 676633-01-5P 676633-03-7P
676633-06-0P 676633-09-3P 676633-12-8P
676633-13-9P 676633-16-2P 676633-18-4P
676633-19-5P 676633-22-0P 676633-25-3P
676633-26-4P 676633-28-6P 676633-29-7P
676633-33-3P 676633-34-4P 676633-39-9P
676633-40-2P 676633-42-4P 676633-43-5P
676633-45-7P 676633-46-8P 676633-48-0P
676633-49-1P 676633-52-6P 676633-53-7P
676633-56-0P 676633-57-1P 676633-60-6P
676633-61-7P 676633-64-0P 676633-65-1P
676633-68-4P 676633-69-5P 676633-72-0P
676633-73-1P 676633-80-0P 676633-83-3P
676633-86-6P 676633-89-9P 676633-90-2P
676633-93-5P 676633-96-8P 676633-99-1P
676634-00-7P 676634-03-0P 676634-06-3P
676634-07-4P 676634-10-9P 676634-11-0P
676634-35-8P 676634-36-9P 676634-39-2P
676634-40-5P 676634-43-8P 676634-44-9P
676634-47-2P 676634-48-3P 676634-51-8P
676634-52-9P 676634-70-1P 676634-71-2P
676634-74-5P 676634-75-6P 676634-80-3P
676634-81-4P 676634-83-6P 676634-84-7P
676634-89-2P 676634-90-5P 676634-92-7P
676634-93-8P 676634-95-0P 676634-96-1P
676635-01-1P 676635-02-2P 676635-04-4P
676635-08-8P 676635-09-9P 676635-12-4P
676635-14-6P 676635-16-8P 676635-17-9P
676635-21-5P 676635-23-7P 676635-24-8P
676635-31-7P 676635-33-9P 676635-35-1P
676635-36-2P 676635-38-4P 676635-39-5P
676635-41-9P 676635-43-1P 676635-45-3P
676635-47-5P 676635-50-0P 676635-56-6P
676635-58-8P 676635-62-4P 676635-68-0P
676635-71-5P 676635-72-6P 676635-83-9P
676635-84-0P 676635-87-3P 676635-88-4P
676635-98-6P 676635-99-7P 676636-02-5P
676636-03-6P 676636-06-9P 676636-07-0P
676636-14-9P 676636-15-0P 676636-18-3P
676636-19-4P 676636-21-8P 676636-22-9P
676636-24-1P 676636-25-2P 676636-27-4P
676636-28-5P 676636-77-4P 676636-79-6P
676636-82-1P 676636-97-8P 676637-00-6P
676637-03-9P 676637-09-5P 676637-11-9P
676637-26-6P 676637-28-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptides for treating resistant tumors)

RN 676631-37-1 HCAPLUS

CN L-Valinamide, 3-chloro-N,β,β-trimethyl-D-phenylalanyl-N-[(1S,2E)-

4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-40-6 HCAPLUS
CN L-Valinamide, 4-chloro-N,β,β-trimethyl-D-phenylalanyl-N-[(1S,2E)-
4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-42-8 HCAPLUS
CN L-Valinamide, N,β,β,3-tetramethyl-D-phenylalanyl-N-[(1S,2E)-4-
ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-44-0 HCAPLUS
CN L-Valinamide, N,β,β,4-tetramethyl-D-phenylalanyl-N-[(1S,2E)-4-
ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-47-3 HCAPLUS
CN L-Valinamide, N,β,β,3,4-pentamethyl-D-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-50-8 HCAPLUS
CN L-Valinamide, N,β,β,3,5-pentamethyl-D-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-52-0 HCAPLUS
CN L-Valinamide, N-methyl-3-(2-thienyl)-D-valyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-55-3 HCAPLUS
CN L-Valinamide, N-methyl-3-(3-thienyl)-D-valyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-57-5 HCAPLUS
CN L-Valinamide, N,β,β,2-tetramethyl-D-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-60-0 HCAPLUS
CN L-Valinamide, 3-benzo[b]thien-3-yl-N-methylvalyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-61-1 HCAPLUS
CN L-Valinamide, 3-benzo[b]thien-3-yl-N-methylvalyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676631-60-0
CMF C29 H43 N3 O4 S

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676631-65-5 HCAPLUS
CN L-Valinamide, 3-chloro-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-68-8 HCAPLUS

CN L-Valinamide, 3-chloro-N,β,β-trimethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-74-6 HCAPLUS

CN L-Valinamide, 4-chloro-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-76-8 HCAPLUS

CN L-Valinamide, 4-chloro-N,β,β-trimethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-81-5 HCAPLUS
CN L-Valinamide, N,β,β,3-tetramethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-84-8 HCAPLUS
CN L-Valinamide, N,β,β,3-tetramethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-88-2 HCAPLUS
CN L-Valinamide, N,β,β,4-tetramethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-89-3 HCAPLUS
CN L-Valinamide, N,β,β,4-tetramethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676631-88-2
CMF C28 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676631-91-7 HCAPLUS
CN L-Valinamide, N,β,β,4-tetramethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676631-92-8 HCAPLUS
CN L-Valinamide, N,β,β,4-tetramethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676631-91-7
CMF C28 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676631-97-3 HCAPLUS
CN L-Valinamide, N,β,β,3,4-pentamethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-00-1 HCAPLUS
CN L-Valinamide, N,β,β,3,4-pentamethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-05-6 HCAPLUS
CN L-Valinamide, N,β,β,3,5-pentamethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-08-9 HCAPLUS
CN L-Valinamide, N,β,β,3,5-pentamethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-14-7 HCAPLUS
CN L-Valinamide, N-methyl-3-(2-thienyl)-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-17-0 HCAPLUS
CN L-Valinamide, N-methyl-3-(2-thienyl)-D-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-22-7 HCAPLUS
CN L-Valinamide, N-methyl-3-(3-thienyl)-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-25-0 HCAPLUS
CN L-Valinamide, N-methyl-3-(3-thienyl)-D-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-28-3 HCAPLUS
CN L-Valinamide, 3-benzo[b]thien-3-yl-N-methylvalyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-33-0 HCAPLUS
CN L-Valinamide, 3-benzo[b]thien-2-yl-N-methylvalyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-38-5 HCAPLUS
CN L-Valinamide, 4-(1,1-dimethylethyl)-N,β,β-trimethylphenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-42-1 HCAPLUS
CN L-Valinamide, N-ethyl-β,β-dimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-51-2 HCAPLUS
CN L-Valinamide, N,β,β,2-tetramethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-53-4 HCAPLUS
CN L-Valinamide, N,β,β,2-tetramethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-55-6 HCAPLUS
CN L-Valinamide, 3-bromo-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-buten-1-yl]-N,3-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-56-7 HCAPLUS
CN L-Valinamide, 3-bromo-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676632-55-6
CMF C27 H42 Br N3 O4

Absolute stereochemistry.

Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676632-58-9 HCAPLUS
CN L-Valinamide, 3-bromo-N,β,β-trimethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-59-0 HCAPLUS
CN L-Valinamide, 3-bromo-N,β,β-trimethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676632-58-9
CMF C27 H42 Br N3 O4

Absolute stereochemistry.

Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676632-61-4 HCAPLUS
CN L-Valinamide, 3-[1,1'-biphenyl]-3-yl-N-methyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-62-5 HCAPLUS
CN L-Valinamide, 3-[1,1'-biphenyl]-3-yl-N-methyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676632-61-4
CMF C33 H47 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676632-65-8 HCAPLUS
CN L-Valinamide, 3-[1,1'-biphenyl]-3-yl-N-methyl-D-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-68-1 HCAPLUS
CN L-Valinamide, 3-ethenyl-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-71-6 HCAPLUS
CN L-Valinamide, 3-ethyl-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-72-7 HCAPLUS
CN L-Valinamide, 3-ethyl-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676632-71-6
CMF C29 H47 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1

CMF C2 H F3 O2

RN 676632-75-0 HCAPLUS
CN L-Valinamide, 4-bromo-N,β,β-trimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-76-1 HCAPLUS
CN L-Valinamide, 4-bromo-N,β,β-trimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676632-75-0
CMF C27 H42 Br N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676632-78-3 HCAPLUS
CN L-Valinamide, 3-[1,1'-biphenyl]-4-yl-N-methyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-79-4 HCAPLUS
CN L-Valinamide, 3-[1,1'-biphenyl]-4-yl-N-methyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676632-78-3
CMF C33 H47 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676632-82-9 HCAPLUS

CN L-Valinamide, 4-carboxy-N,β,β-trimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-83-0 HCAPLUS

CN L-Valinamide, 4-carboxy-N,β,β-trimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676632-82-9
CMF C28 H43 N3 O6

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676632-86-3 HCAPLUS
CN L-Valinamide, 3-methoxy-N,β,β-trimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-87-4 HCAPLUS
CN L-Valinamide, 3-methoxy-N,β,β-trimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676632-86-3
CMF C28 H45 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676632-90-9 HCAPLUS
CN L-Valinamide, 3-hydroxy-N,β,β-trimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-91-0 HCAPLUS
CN L-Valinamide, 3-hydroxy-N,β,β-trimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 676632-90-9
CMF C27 H43 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676632-94-3 HCAPLUS
CN L-Valinamide, N,3-dimethyl-4-phenyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-97-6 HCAPLUS
CN L-Valinamide, N,3-dimethyl-4-phenyl-D-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676632-99-8 HCAPLUS
CN L-Valinamide, N-methyl-3-pentyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-01-5 HCAPLUS
CN L-Valinamide, N-methyl-3-pentyl-D-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-03-7 HCAPLUS
CN L-Valinamide, N,N,β,β-tetramethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-06-0 HCAPLUS
CN L-Valinamide, N-(2-hydroxyethyl)-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-09-3 HCAPLUS

CN L-Valinamide, 2-methoxy-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-12-8 HCAPLUS

CN L-Valinamide, 2-methoxy-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-13-9 HCAPLUS

CN L-Valinamide, 2-methoxy-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-12-8
CMF C28 H45 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676633-16-2 HCAPLUS
CN L-Valinamide, N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-18-4 HCAPLUS
CN L-Valinamide, N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-3-carboxy-

1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-19-5 HCAPLUS
CN L-Valinamide, N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-18-4
CMF C28 H45 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676633-22-0 HCAPLUS
CN L-Valinamide, 2-methoxy-N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl-,

monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-25-3 HCAPLUS
CN L-Valinamide, 2-methoxy-N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-26-4 HCAPLUS
CN L-Valinamide, 2-methoxy-N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-25-3
CMF C29 H47 N3 O6

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676633-28-6 HCAPLUS
CN L-Valinamide, 3-fluoro-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-29-7 HCAPLUS
CN L-Valinamide, 3-fluoro-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-28-6
CMF C27 H42 F N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676633-33-3 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-3-(trifluoromethyl)-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-34-4 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-3-(trifluoromethyl)-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-33-3
CMF C28 H42 F3 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676633-39-9 HCAPLUS
CN L-Valinamide, 3,5-difluoro-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-40-2 HCAPLUS
CN L-Valinamide, 3,5-difluoro-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-39-9
CMF C27 H41 F2 N3 O4

Absolute stereochemistry.

Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676633-42-4 HCAPLUS
CN L-Valinamide, 3,5-difluoro-N,β,β-trimethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-43-5 HCAPLUS
CN L-Valinamide, 3,5-difluoro-N,β,β-trimethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-42-4
CMF C27 H41 F2 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676633-45-7 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-3,5-bis(trifluoromethyl)-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-46-8 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-3,5-bis(trifluoromethyl)-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-

dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-45-7
CMF C29 H41 F6 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676633-48-0 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-3,5-bis(trifluoromethyl)-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-49-1 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-3,5-bis(trifluoromethyl)-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-48-0
CMF C29 H41 F6 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676633-52-6 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-O-(1-methylethyl)-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-53-7 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-O-(1-methylethyl)-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-52-6
CMF C30 H49 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676633-56-0 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-O-(1-methylethyl)-D-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-57-1 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-O-(1-methylethyl)-D-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-56-0
CMF C30 H49 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676633-60-6 HCAPLUS
CN L-Valinamide, 3-cyclohexyl-N-methyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-61-7 HCAPLUS
CN L-Valinamide, 3-cyclohexyl-N-methyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-60-6
CMF C27 H49 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676633-64-0 HCAPLUS
CN L-Valinamide, (2S)-N-methyl-2-(1-phenylcyclopentyl)glycyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-65-1 HCAPLUS

CN L-Valinamide, (2S)-N-methyl-2-(1-phenylcyclopentyl)glycyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-64-0
CMF C29 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676633-68-4 HCAPLUS
CN L-Valinamide, (2R)-N-methyl-2-(1-phenylcyclopentyl)glycyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-69-5 HCAPLUS
CN L-Valinamide, (2R)-N-methyl-2-(1-phenylcyclopentyl)glycyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-68-4
CMF C29 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676633-72-0 HCAPLUS
CN L-Valinamide, N-methyl-2-(1-phenylcyclohexyl)glycyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-73-1 HCAPLUS
CN L-Valinamide, N-methyl-2-(1-phenylcyclohexyl)glycyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-72-0
CMF C30 H47 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676633-80-0 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S)-1-[(1E)-2-carboxy-1-propenyl]pentyl]-N,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 676633-83-3 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(2-methylpropyl)-2-pentenyl]-N,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



● HCl

RN 676633-86-6 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-heptenyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 676633-89-9 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-pentenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676633-90-2 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-pentenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-89-9
CMF C28 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676633-93-5 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N-methyl-3-(methylthio)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 676633-96-8 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl-3-(methylthio)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 676633-99-1 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676634-00-7 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl-3-(methylsulfonyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676633-99-1
CMF C27 H43 N3 O6 S

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676634-03-0 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-[[(4-methoxyphenyl)methyl]thio]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676634-06-3 HCAPLUS
CN L-Valinamide, N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-[[(4-methoxyphenyl)methyl]thio]-N-methyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676634-07-4 HCAPLUS
CN L-Valinamide, N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-[[(4-methoxyphenyl)methyl]thio]-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676634-06-3
CMF C35 H51 N3 O6 S

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676634-10-9 HCAPLUS
CN L-Valinamide, N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl-3-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676634-11-0 HCAPLUS
CN L-Valinamide, N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl-3-(methylthio)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676634-10-9
CMF C28 H45 N3 O5 S

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676634-35-8 HCAPLUS
CN L-Valinamide, 4-benzoyl-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676634-36-9 HCAPLUS
CN L-Valinamide, 4-benzoyl-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676634-35-8

CMF C34 H47 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676634-39-2 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(2-methylpropyl)-2-butenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676634-40-5 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(2-methylpropyl)-2-butenyl]-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676634-39-2
CMF C27 H43 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676634-43-8 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(2-methylpropyl)-2-butenyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676634-44-9 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(2-methylpropyl)-2-butenyl]-3-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676634-43-8
CMF C27 H43 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676634-47-2 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-ethyl-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676634-48-3 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-ethyl-3-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676634-47-2
CMF C28 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676634-51-8 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676634-52-9 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-ethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676634-51-8
CMF C27 H43 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676634-70-1 HCAPLUS
CN L-Valinamide, N,β-dimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676634-71-2 HCAPLUS
CN L-Valinamide, N,β-dimethylphenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676634-70-1
CMF C26 H41 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676634-74-5 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676634-75-6 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676634-74-5
CMF C25 H39 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676634-80-3 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(2-methylpropyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676634-81-4 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(2-methylpropyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676634-80-3
CMF C28 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676634-83-6 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676634-84-7 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl-, mono(trifluoroacetate)

(9CI) (CA INDEX NAME)

CM 1

CRN 676634-83-6
CMF C26 H41 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676634-89-2 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-amino-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676634-90-5 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-amino-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676634-89-2
CMF C27 H44 N4 O3

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676634-92-7 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N,3-dimethyl-N-[(1S,2E)-3-methyl-4-(methylamino)-1-(1-methylethyl)-4-oxo-2-butenyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676634-93-8 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N,3-dimethyl-N-[(1S,2E)-3-methyl-4-(methylamino)-1-(1-methylethyl)-4-oxo-2-butenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676634-92-7
CMF C28 H46 N4 O3

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676634-95-0 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-[(2-cyanoethyl)amino]-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676634-96-1 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-[(2-cyanoethyl)amino]-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676634-95-0
CMF C30 H47 N5 O3

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676635-01-1 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-[(4-azidophenyl)amino]-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676635-02-2 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-[(4-azidophenyl)amino]-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676635-01-1
CMF C33 H47 N7 O3

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676635-04-4 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N,3-dimethyl-N-[(1S,2E)-3-methyl-1-(1-methylethyl)-4-oxo-4-[(2-phenylethyl)amino]-2-butenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 676635-08-8 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-[[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]methylamino]-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676635-09-9 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-[[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]methylamino]-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676635-08-8
CMF C36 H58 N4 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676635-12-4 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N,3-dimethyl-N-[(1S,2E)-3-methyl-1-(1-methylethyl)-4-oxo-4-(2-thienylmethoxy)-2-butenyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676635-14-6 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N,3-dimethyl-N-[(1S,2E)-3-methyl-1-(1-methylethyl)-4-(octyloxy)-4-oxo-2-butenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676635-16-8 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2Z)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676635-17-9 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2Z)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676635-16-8
CMF C27 H43 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676635-21-5 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-propenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676635-20-4
CMF C26 H41 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676635-23-7 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(2-propenyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676635-24-8 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(2-propenyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676635-23-7
CMF C27 H41 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676635-31-7 HCAPLUS
CN L-Valinamide, 4,5-didehydro-N,3-dimethylisoleucyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 676635-33-9 HCAPLUS

CN L-Isoleucinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676635-32-8
CMF C28 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676635-35-1 HCAPLUS

CN L-Valinamide, N,β,β,β-trimethyl-L-phenylalanyl-N-[(1R,3S)-3-carboxy-1-(1-methylethyl)butyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676635-36-2 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1R,3S)-3-carboxy-1-(1-methylethyl)butyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676635-35-1
CMF C27 H45 N3 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676635-38-4 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1R,3R)-3-carboxy-1-(1-methylethyl)butyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676635-39-5 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1R,3R)-3-carboxy-1-(1-methylethyl)butyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676635-38-4
CMF C27 H45 N3 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676635-41-9 HCAPLUS

CN L-Valinamide, β,β-diethyl-N-methyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 676635-43-1 HCAPLUS

CN L-Valinamide, β,β-diethyl-N-methyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676635-45-3 HCAPLUS

CN L-Valinamide, (βS)-N,β-dimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676635-47-5 HCAPLUS

CN L-Valinamide, N-methyl-O-(phenylmethyl)-L-threonyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676635-50-0 HCAPLUS
CN L-Valinamide, 3-(1-naphthalenyl)-L-alanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676635-56-6 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-D-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676635-58-8 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-

carboxy-1-(phenylmethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676635-62-4 HCAPLUS
CN L-Valinamide, L-leucyl-N-[(1R,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676635-68-0 HCAPLUS
CN L-Valinamide, (2S)-N-methyl-2-(1-phenylcyclopropyl)glycyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676635-71-5 HCAPLUS
CN L-Valinamide, (2R)-N-methyl-2-(1-phenylcyclopropyl)glycyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 676635-72-6 HCAPLUS
CN L-Valinamide, (2R)-N-methyl-2-(1-phenylcyclopropyl)glycyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676635-71-5
CMF C27 H41 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676635-83-9 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-4-[(1E)-2-phenylethenyl]-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 676635-84-0 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-4-[(1E)-2-phenylethenyl]-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676635-83-9
CMF C35 H49 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676635-87-3 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-4-[(1E)-2-phenylethenyl]-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 676635-88-4 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-4-[(1E)-2-phenylethenyl]-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676635-87-3
CMF C35 H49 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676635-98-6 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-fluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 676635-99-7 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-fluoro-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676635-98-6
CMF C26 H40 F N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676636-02-5 HCAPLUS
CN L-Valinamide, 3-[[(4-methoxyphenyl)methyl]thio]-N-methyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676636-03-6 HCAPLUS
CN L-Valinamide, 3-[[(4-methoxyphenyl)methyl]thio]-N-methyl-L-valyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676636-02-5
CMF C29 H47 N3 O5 S

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676636-06-9 HCAPLUS
CN L-Valinamide, N-ethyl-β,β-dimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676636-07-0 HCAPLUS
CN L-Valinamide, N-ethyl-β,β-dimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676636-06-9
CMF C28 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676636-14-9 HCAPLUS
CN L-Valinamide, N-(2-hydroxyethyl)-β,β-dimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676636-15-0 HCAPLUS
CN L-Valinamide, N-(2-hydroxyethyl)-β,β-dimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 676636-14-9
CMF C28 H45 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676636-18-3 HCAPLUS

CN L-Valinamide, (βR)-N,β-dimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676636-19-4 HCAPLUS

CN L-Valinamide, (βR)-N,β-dimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676636-18-3
CMF C26 H41 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676636-21-8 HCAPLUS

CN L-Valinamide, 3-acetyl-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676636-22-9 HCAPLUS

CN L-Valinamide, 3-acetyl-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676636-21-8
CMF C29 H45 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676636-24-1 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-hydroxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676636-25-2 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-hydroxy-N-methyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 676636-24-1
CMF C26 H41 N3 O5

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676636-27-4 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1R,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676636-28-5 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1R,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676636-27-4
CMF C27 H43 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676636-77-4 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N-methyl-3-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676636-79-6 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N-methyl-3-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676636-82-1 HCAPLUS

CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-3-[[(4-methoxyphenyl)methyl]thio]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676636-97-8 HCAPLUS

CN L-Valinamide, 2-methoxy-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676637-00-6 HCAPLUS

CN L-Valinamide, N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676637-03-9 HCAPLUS

CN L-Valinamide, 2-methoxy-N,O,β,β-tetramethyl-L-tyrosyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676637-09-5 HCAPLUS
CN L-Valinamide, N,β,β,3-tetramethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676631-81-5
CMF C28 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676637-11-9 HCAPLUS
CN L-Valinamide, N,β,β,3-tetramethyl-D-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-butenyl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 676631-84-8
CMF C28 H45 N3 O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 676637-26-6 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S)-1-[(1E)-2-carboxy-1-propenyl]pentyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676637-28-8 HCAPLUS
CN L-Valinamide, N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(2-methylpropyl)-2-pentenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 676637-13-1P 676637-15-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of peptides for treating resistant tumors)

RN 676637-13-1 HCAPLUS

CN L-Valinamide, N,4-bis[(1,1-dimethylethoxy)carbonyl]-N,β,β-trimethylphenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 676637-15-3 HCAPLUS

CN L-Valinamide, N,3-dimethyl-4-phenylvalyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-butenyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IC ICM A61K031-191
ICS A61K031-194; A61P035-00; A61K031-192; A61K031-195

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1
ST peptide prepn antitumor resistant tumor; structure activity
antitumor peptide prepn
IT P-glycoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MDR1; preparation of peptides for treating resistant tumors)
IT Structure-activity relationship
(antitumor; preparation of peptides for treating resistant tumors)
IT Antitumor agents
Neoplasm
(preparation of peptides for treating resistant tumors)
IT 167158-86-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MDR-1 inhibitor; preparation of peptides for treating resistant
tumors)
IT 57-22-7, Vincristine 865-21-4, Vinblastine 33069-62-4, Paclitaxel
71486-22-1, Vinorelbine 114977-28-5, Docetaxel
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chemotherapeutic agent; preparation of peptides for treating resistant
tumors)
IT 676628-40-3P 676631-63-3P 676631-71-3P
676631-78-0P 676631-86-0P 676631-94-0P
676632-03-4P 676632-11-4P 676632-20-5P
676632-31-8P 676632-40-9P 676632-45-4P
676632-48-7P 676632-66-9P 676632-69-2P
676634-25-6P 676635-06-6P 676642-03-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of peptides for treating resistant tumors)
IT 169181-24-2P 228266-42-0P 228266-48-6P 228266-49-7P 500229-47-0P
676631-37-1P 676631-40-6P 676631-42-8P
676631-44-0P 676631-47-3P 676631-50-8P
676631-52-0P 676631-55-3P 676631-57-5P
676631-60-0P 676631-61-1P 676631-65-5P
676631-68-8P 676631-74-6P 676631-76-8P
676631-81-5P 676631-84-8P 676631-88-2P
676631-89-3P 676631-91-7P 676631-92-8P
676631-97-3P 676632-00-1P 676632-05-6P
676632-08-9P 676632-14-7P 676632-17-0P
676632-22-7P 676632-25-0P 676632-28-3P
676632-33-0P 676632-38-5P 676632-42-1P
676632-51-2P 676632-53-4P 676632-55-6P
676632-56-7P 676632-58-9P 676632-59-0P
676632-61-4P 676632-62-5P 676632-65-8P
676632-68-1P 676632-71-6P 676632-72-7P
676632-75-0P 676632-76-1P 676632-78-3P
676632-79-4P 676632-82-9P 676632-83-0P
676632-86-3P 676632-87-4P 676632-90-9P
676632-91-0P 676632-94-3P 676632-97-6P
676632-99-8P 676633-01-5P 676633-03-7P
676633-06-0P 676633-09-3P 676633-12-8P
676633-13-9P 676633-16-2P 676633-18-4P
676633-19-5P 676633-22-0P 676633-25-3P
676633-26-4P 676633-28-6P 676633-29-7P
676633-33-3P 676633-34-4P 676633-39-9P
676633-40-2P 676633-42-4P 676633-43-5P
676633-45-7P 676633-46-8P 676633-48-0P
676633-49-1P 676633-52-6P 676633-53-7P

676633-56-0P 676633-57-1P 676633-60-6P
676633-61-7P 676633-64-0P 676633-65-1P
676633-68-4P 676633-69-5P 676633-72-0P
676633-73-1P 676633-77-5P 676633-80-0P
676633-83-3P 676633-86-6P 676633-89-9P
676633-90-2P 676633-93-5P 676633-96-8P
676633-99-1P 676634-00-7P 676634-03-0P
676634-06-3P 676634-07-4P 676634-10-9P
676634-11-0P 676634-14-3P 676634-17-6P 676634-18-7P
676634-21-2P 676634-24-5P 676634-28-9P 676634-31-4P 676634-32-5P
676634-35-8P 676634-36-9P 676634-39-2P
676634-40-5P 676634-43-8P 676634-44-9P
676634-47-2P 676634-48-3P 676634-51-8P
676634-52-9P 676634-55-2P 676634-56-3P 676634-59-6P
676634-60-9P 676634-63-2P 676634-64-3P 676634-66-5P 676634-67-6P
676634-70-1P 676634-71-2P 676634-74-5P
676634-75-6P 676634-77-8P 676634-78-9P 676634-80-3P
676634-81-4P 676634-83-6P 676634-84-7P
676634-86-9P 676634-87-0P 676634-89-2P 676634-90-5P
676634-92-7P 676634-93-8P 676634-95-0P
676634-96-1P 676634-98-3P 676634-99-4P 676635-01-1P
676635-02-2P 676635-04-4P 676635-08-8P
676635-09-9P 676635-12-4P 676635-14-6P
676635-16-8P 676635-17-9P 676635-21-5P
676635-23-7P 676635-24-8P 676635-27-1P 676635-28-2P
676635-31-7P 676635-32-8P 676635-33-9P
676635-35-1P 676635-36-2P 676635-38-4P
676635-39-5P 676635-41-9P 676635-43-1P
676635-45-3P 676635-47-5P 676635-50-0P
676635-52-2P 676635-56-6P 676635-58-8P 676635-60-2P
676635-62-4P 676635-64-6P 676635-68-0P
676635-71-5P 676635-72-6P 676635-75-9P 676635-76-0P
676635-79-3P 676635-80-6P 676635-83-9P 676635-84-0P
676635-87-3P 676635-88-4P 676635-93-1P 676635-94-2P
676635-98-6P 676635-99-7P 676636-02-5P
676636-03-6P 676636-06-9P 676636-07-0P
676636-10-5P 676636-11-6P 676636-14-9P 676636-15-0P
676636-18-3P 676636-19-4P 676636-21-8P
676636-22-9P 676636-24-1P 676636-25-2P
676636-27-4P 676636-28-5P 676636-77-4P
676636-79-6P 676636-82-1P 676636-87-6P
676636-97-8P 676637-00-6P 676637-03-9P
676637-09-5P 676637-11-9P 676637-26-6P
676637-28-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides for treating resistant tumors)

IT 676637-30-2P 676637-32-4P 676637-34-6P 676637-75-5P 676637-78-8P
676643-79-1P 676643-80-4P 676643-82-6P 676643-83-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides for treating resistant tumors)

IT 64-04-0, Phenethylamine 75-03-6, Iodoethane 98-03-3, Thiophene-2-aldehyde 98-80-6, Phenylboronic acid 100-66-3, Methoxybenzene, reactions 104-87-0 104-88-1, p-Chlorobenzaldehyde, reactions 111-87-5, 1 Octanol, reactions 114-76-1, Phenylpyruvic acid sodium salt 151-10-0, 1,3-Dimethoxybenzene 151-18-8, 3 Aminopropionitrile 156-06-9 328-51-8, 2-Oxooctanoic acid 456-48-4,

m-Fluorobenzaldehyde 461-72-3, Hydantoin 498-62-4, Thiophene-3-aldehyde 529-20-4, o-Tolualdehyde 540-51-2, 2 Bromoethanol 543-24-8, Acetylglycine 556-82-1, 3 Methyl 2 buten 1 ol 587-04-2, m-Chlorobenzaldehyde 591-31-1, m-Anisaldehyde 620-23-5, m-Tolualdehyde 628-21-7, 1,4-Diiodobutane 628-77-3, 1,5-Diiodopentane 636-72-6, 2 Thiophenemethanol 710-11-2, 2-Oxo-4-phenylbutyric acid 759-05-7 939-97-9, p tert-Butylbenzaldehyde 1121-57-9, 1 Isocyanocyclohexene 2280-27-5 2605-67-6 3132-99-8, m-Bromobenzaldehyde 3282-30-2, Pivaloyl chloride 3541-37-5, Thianaphthene-2-carboxaldehyde 4530-20-5 5381-20-4, Thianaphthene-3-carboxaldehyde 5717-37-3, (Carbethoxyethylidene)triphenylphosphorane 5779-95-3, 3,5-Dimethylbenzaldehyde 5973-71-7, 3,4-Dimethylbenzaldehyde 13139-15-6 13734-34-4, N-tert-Butoxycarbonyl-L-phenylalanine 18962-05-5, 4-Isopropoxybenzaldehyde 21744-88-7, Cyclopropanecarboxaldehyde, 1 phenyl 23082-30-6 25080-84-6 40447-58-3 55447-00-2 59752-74-8 64263-80-5 90600-20-7 91159-79-4 97674-02-7, Tributyl(1-ethoxyvinyl)tin 100564-78-1 107905-52-2 112898-23-4 120944-75-4 145432-51-5 184434-18-2 184434-19-3 228266-38-4 228266-40-8 500229-32-3 610786-69-1 610786-70-4 630424-73-6 676630-99-2 676631-15-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of peptides for treating resistant tumors)

IT 13781-71-0P 15504-41-3P 26269-45-4P 61676-25-3P 66386-16-1P 68262-20-4P 79069-51-5P 82706-45-4P 83396-71-8P 87694-50-6P 89000-97-5P 91133-59-4P 91496-52-5P 93634-54-9P 93634-55-0P 96406-06-3P 127106-02-9P 128437-36-5P 128437-66-1P 128437-74-1P 138802-17-2P 160785-01-3P 161479-50-1P 207910-81-4P 207910-88-1P 207910-90-5P 208521-14-6P 213206-68-9P 564441-48-1P 564441-50-5P 676626-71-4P 676626-79-2P 676626-83-8P 676626-85-0P 676626-89-4P 676626-91-8P 676626-93-0P 676626-95-2P 676626-97-4P 676626-99-6P 676627-01-3P 676627-02-4P 676627-05-7P 676627-06-8P 676627-09-1P 676627-11-5P 676627-13-7P 676627-15-9P 676627-17-1P 676627-18-2P 676627-20-6P 676627-21-7P 676627-23-9P 676627-25-1P 676627-27-3P 676627-31-9P 676627-33-1P 676627-35-3P 676627-37-5P 676627-39-7P 676627-42-2P 676627-44-4P 676627-46-6P 676627-48-8P 676627-50-2P 676627-53-5P 676627-55-7P 676627-58-0P 676627-60-4P 676627-63-7P 676627-65-9P 676627-67-1P 676627-69-3P 676627-71-7P 676627-73-9P 676627-75-1P 676627-77-3P 676627-79-5P 676627-81-9P 676627-84-2P 676627-86-4P 676627-88-6P 676627-90-0P 676627-92-2P 676627-94-4P 676627-97-7P 676627-99-9P 676628-01-6P 676628-03-8P 676628-05-0P 676628-07-2P 676628-09-4P 676628-10-7P 676628-12-9P 676628-14-1P 676628-16-3P 676628-18-5P 676628-20-9P 676628-22-1P 676628-24-3P 676628-26-5P 676628-28-7P 676628-30-1P 676628-32-3P 676628-34-5P 676628-36-7P 676628-38-9P 676628-43-6P 676628-45-8P 676628-48-1P 676628-50-5P 676628-52-7P 676628-54-9P 676628-56-1P 676628-58-3P 676628-60-7P 676628-62-9P 676628-64-1P 676628-66-3P 676628-68-5P 676628-70-9P 676628-72-1P 676628-74-3P 676628-76-5P 676628-78-7P 676628-80-1P 676628-82-3P 676628-84-5P 676628-86-7P 676628-88-9P 676628-90-3P 676628-92-5P 676628-94-7P 676628-96-9P 676628-98-1P 676629-00-8P 676629-02-0P 676629-04-2P 676629-06-4P 676629-08-6P 676629-10-0P 676629-12-2P 676629-14-4P 676629-16-6P 676629-18-8P 676629-20-2P 676629-22-4P 676629-23-5P 676629-25-7P 676629-27-9P 676629-29-1P 676629-31-5P 676629-33-7P 676629-35-9P 676629-37-1P 676629-39-3P 676629-41-7P 676629-43-9P 676629-45-1P 676629-47-3P 676629-49-5P 676629-51-9P 676629-53-1P 676629-55-3P 676629-57-5P 676629-60-0P 676629-62-2P 676629-65-5P 676629-67-7P 676629-71-3P 676629-73-5P 676629-76-8P 676629-78-0P 676629-80-4P 676629-83-7P 676629-86-0P 676629-88-2P 676629-90-6P 676629-93-9P 676629-96-2P 676629-98-4P 676630-01-6P 676630-04-9P 676630-06-1P 676630-09-4P 676630-12-9P 676630-17-4P 676630-20-9P 676630-23-2P 676630-26-5P

676630-29-8P 676630-32-3P 676630-35-6P 676630-37-8P 676630-40-3P
676630-42-5P 676630-45-8P 676630-47-0P 676630-50-5P 676630-54-9P
676630-57-2P 676630-59-4P 676630-62-9P 676630-65-2P 676630-68-5P
676630-70-9P 676630-73-2P 676630-83-4P 676630-85-6P 676630-87-8P
676630-91-4P 676631-04-2P 676631-23-5P 676631-26-8P 676636-30-9P
676636-32-1P 676636-34-3P 676636-35-4P 676636-38-7P 676636-40-1P
676636-42-3P 676636-45-6P 676636-47-8P 676636-49-0P 676636-51-4P
676636-59-2P 676637-05-1P 676637-07-3P 676637-13-1P
676637-15-3P 676637-17-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of peptides for treating resistant tumors)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his nofi

     (FILE 'HOME' ENTERED AT 07:48:59 ON 10 MAR 2009)

     FILE 'REGISTRY' ENTERED AT 07:49:09 ON 10 MAR 2009
                E 676633-03-7/RN
                E 676633-03-7/RN
L1           12 SEA ABB=ON  PLU=ON  (676633-01-5/RN OR 676633-02-6/RN OR
                676633-03-7/RN OR 676633-04-8/RN OR 676633-05-9/RN OR 676633-06
                -0/RN OR 676633-07-1/RN OR 676633-08-2/RN OR 676633-09-3/RN OR
                676633-10-6/RN OR 676633-11-7/RN OR 676633-12-8/RN)
L2            0 SEA ABB=ON  PLU=ON  L1 (L) "L()VALINAMIDE"
L3            5 SEA ABB=ON  PLU=ON  L1 AND "L()VALINAMIDE"
                E 676633-13-9/RN
L4           22 SEA ABB=ON  PLU=ON  (676633-13-9/RN OR 676633-14-0/RN OR
                676633-15-1/RN OR 676633-16-2/RN OR 676633-17-3/RN OR 676633-18
                -4/RN OR 676633-19-5/RN OR 676633-20-8/RN OR 676633-21-9/RN OR
                676633-22-0/RN OR 676633-23-1/RN OR 676633-24-2/RN OR 676633-25
                -3/RN OR 676633-26-4/RN OR 676633-27-5/RN OR 676633-28-6/RN OR
                676633-29-7/RN OR 676633-30-0/RN OR 676633-31-1/RN OR 676633-32
                -2/RN OR 676633-33-3/RN OR 676633-34-4/RN)
L5           11 SEA ABB=ON  PLU=ON  L4 AND "L()VALINAMIDE"
                E 676633-39-9/RN
L6           22 SEA ABB=ON  PLU=ON  (676633-39-9/RN OR 676633-40-2/RN OR
                676633-41-3/RN OR 676633-42-4/RN OR 676633-43-5/RN OR 676633-44
                -6/RN OR 676633-45-7/RN OR 676633-46-8/RN OR 676633-47-9/RN OR
                676633-48-0/RN OR 676633-49-1/RN OR 676633-50-4/RN OR 676633-51
                -5/RN OR 676633-52-6/RN OR 676633-53-7/RN OR 676633-54-8/RN OR
                676633-55-9/RN OR 676633-56-0/RN OR 676633-57-1/RN OR 676633-58
                -2/RN OR 676633-59-3/RN OR 676633-60-6/RN)
L7           13 SEA ABB=ON  PLU=ON  L6 AND "L()VALINAMIDE"
L8            0 SEA ABB=ON  PLU=ON  (L3 OR L5 OR L7) AND (HEXENO? OR HEXENOATE?
                 OR HEPT?)
                D COST
                E 676633-61-7/RN
L9           20 SEA ABB=ON  PLU=ON  (676633-61-7/RN OR 676633-62-8/RN OR
                676633-63-9/RN OR 676633-64-0/RN OR 676633-65-1/RN OR 676633-66
                -2/RN OR 676633-67-3/RN OR 676633-68-4/RN OR 676633-69-5/RN OR
                676633-70-8/RN OR 676633-71-9/RN OR 676633-72-0/RN OR 676633-73
                -1/RN OR 676633-74-2/RN OR 676633-75-3/RN OR 676633-76-4/RN OR
                676633-77-5/RN OR 676633-78-6/RN OR 676633-79-7/RN OR 676633-80
                -0/RN)
L10           8 SEA ABB=ON  PLU=ON  L9 AND "L()VALINAMIDE"
L11           0 SEA ABB=ON  PLU=ON  (L3 OR L5 OR L7 OR L10) AND ALLOTHREONINAMI
                DE
L12           0 SEA ABB=ON  PLU=ON  (L3 OR L5 OR L7 OR L10) AND TYROSINAMIDE
                E 676633-83-3/RN
L13          46 SEA ABB=ON  PLU=ON  (676633-83-3/RN OR 676633-84-4/RN OR
                676633-85-5/RN OR 676633-86-6/RN OR 676633-87-7/RN OR 676633-88
                -8/RN OR 676633-89-9/RN OR 676633-90-2/RN OR 676633-91-3/RN OR
                676633-92-4/RN OR 676633-93-5/RN OR 676633-94-6/RN OR 676633-95
                -7/RN OR 676633-96-8/RN OR 676633-97-9/RN OR 676633-98-0/RN OR
                676633-99-1/RN OR 676634-00-7/RN OR 676634-01-8/RN OR 676634-02
                -9/RN OR 676634-03-0/RN OR 676634-04-1/RN OR 676634-05-2/RN OR
                676634-06-3/RN OR 676634-07-4/RN OR 676634-08-5/RN OR 676634-09
                -6/RN OR 676634-10-9/RN OR 676634-11-0/RN OR 676634-12-1/RN OR
                676634-13-2/RN OR 676634-14-3/RN OR 676634-15-4/RN OR 676634-16
                -5/RN OR 676634-17-6/RN OR 676634-18-7/RN OR 676634-19-8/RN OR
```

676634-20-1/RN OR 676634-21-2/RN OR 676634-22-3/RN OR 676634-23-4/RN OR 676634-24-5/RN OR 676634-25-6/RN OR 676634-26-7/RN OR 676634-27-8/RN OR 676634-28-9/RN)

L14 13 SEA ABB=ON PLU=ON L13 AND "L()VALINAMIDE"
E 676634-31-4/RN

L15 45 SEA ABB=ON PLU=ON (676634-31-4/RN OR 676634-32-5/RN OR 676634-33-6/RN OR 676634-34-7/RN OR 676634-35-8/RN OR 676634-36-9/RN OR 676634-37-0/RN OR 676634-38-1/RN OR 676634-39-2/RN OR 676634-40-5/RN OR 676634-41-6/RN OR 676634-42-7/RN OR 676634-43-8/RN OR 676634-44-9/RN OR 676634-45-0/RN OR 676634-46-1/RN OR 676634-47-2/RN OR 676634-48-3/RN OR 676634-49-4/RN OR 676634-50-7/RN OR 676634-51-8/RN OR 676634-52-9/RN OR 676634-53-0/RN OR 676634-54-1/RN OR 676634-55-2/RN OR 676634-56-3/RN OR 676634-57-4/RN OR 676634-58-5/RN OR 676634-59-6/RN OR 676634-60-9/RN OR 676634-61-0/RN OR 676634-62-1/RN OR 676634-63-2/RN OR 676634-64-3/RN OR 676634-65-4/RN OR 676634-66-5/RN OR 676634-67-6/RN OR 676634-68-7/RN OR 676634-69-8/RN OR 676634-70-1/RN OR 676634-71-2/RN OR 676634-72-3/RN OR 676634-73-4/RN OR 676634-74-5/RN OR 676634-75-6/RN)

L16 14 SEA ABB=ON PLU=ON L15 AND "L()VALINAMIDE"

L17 0 SEA ABB=ON PLU=ON (L14 OR L16) AND TYROSINAMIDE

L18 0 SEA ABB=ON PLU=ON (L14 OR L16) AND HEXENO?

L19 0 SEA ABB=ON PLU=ON (L14 OR L16) AND PHENYLALANIMIDE
E 676634-77-8/RN

L20 58 SEA ABB=ON PLU=ON (676634-77-8/RN OR 676634-78-9/RN OR 676634-79-0/RN OR 676634-80-3/RN OR 676634-81-4/RN OR 676634-82-5/RN OR 676634-83-6/RN OR 676634-84-7/RN OR 676634-85-8/RN OR 676634-86-9/RN OR 676634-87-0/RN OR 676634-88-1/RN OR 676634-89-2/RN OR 676634-90-5/RN OR 676634-91-6/RN OR 676634-92-7/RN OR 676634-93-8/RN OR 676634-94-9/RN OR 676634-95-0/RN OR 676634-96-1/RN OR 676634-97-2/RN OR 676634-98-3/RN OR 676634-99-4/RN OR 676635-00-0/RN OR 676635-01-1/RN OR 676635-02-2/RN OR 676635-03-3/RN OR 676635-04-4/RN OR 676635-05-5/RN OR 676635-06-6/RN OR 676635-07-7/RN OR 676635-08-8/RN OR 676635-09-9/RN OR 676635-10-2/RN OR 676635-11-3/RN OR 676635-12-4/RN OR 676635-13-5/RN OR 676635-14-6/RN OR 676635-15-7/RN OR 676635-16-8/RN OR 676635-17-9/RN OR 676635-18-0/RN OR 676635-19-1/RN OR 676635-20-4/RN OR 676635-21-5/RN OR 676635-22-6/RN OR 676635-23-7/RN OR 676635-24-8/RN OR 676635-25-9/RN OR 676635-26-0/RN OR 676635-27-1/RN OR 676635-28-2/RN OR 676635-29-3/RN OR 676635-30-6/RN OR 676635-31-7/RN OR 676635-32-8/RN OR 676635-33-9/RN OR 676635-34-0/RN)

L21 25 SEA ABB=ON PLU=ON L20 AND "L()VALINAMIDE"
E 676635-35-1/RN

L22 67 SEA ABB=ON PLU=ON (676635-33-9/RN OR 676635-34-0/RN OR 676635-35-1/RN OR 676635-36-2/RN OR 676635-37-3/RN OR 676635-38-4/RN OR 676635-39-5/RN OR 676635-40-8/RN OR 676635-41-9/RN OR 676635-42-0/RN OR 676635-43-1/RN OR 676635-44-2/RN OR 676635-45-3/RN OR 676635-46-4/RN OR 676635-47-5/RN OR 676635-48-6/RN OR 676635-49-7/RN OR 676635-50-0/RN OR 676635-51-1/RN OR 676635-52-2/RN OR 676635-53-3/RN OR 676635-54-4/RN OR 676635-55-5/RN OR 676635-56-6/RN OR 676635-57-7/RN OR 676635-58-8/RN OR 676635-59-9/RN OR 676635-60-2/RN OR 676635-61-3/RN OR 676635-62-4/RN OR 676635-63-5/RN OR 676635-64-6/RN OR 676635-65-7/RN OR 676635-66-8/RN OR 676635-67-9/RN OR 676635-68-0/RN OR 676635-69-1/RN OR 676635-70-4/RN OR 676635-71-5/RN OR 676635-72-6/RN OR 676635-73-7/RN OR 676635-74-8/RN OR 676635-75-9/RN OR 676635-76-0/RN OR 676635-77-1/RN OR 676635-78-2/RN OR 676635-79-3/RN OR 676635-80-6/RN OR 676635-81-7/RN OR 676635-82-8/RN OR 676635-83-9/RN OR 676635-84-0/RN OR 676635-85-1/RN OR 676635-86-2/RN OR 676635-87-3/RN OR 676635-88-4/RN OR 676635-89-5/RN OR 676635-90-8/RN OR

676635-91-9/RN OR 676635-92-0/RN OR 676635-93-1/RN OR 676635-94-2/RN OR 676635-95-3/RN OR 676635-96-4/RN OR 676635-97-5/RN OR 676635-98-6/RN OR 676635-99-7/RN)
D COST

L23 21 SEA ABB=ON PLU=ON L22 AND "L()VALINAMIDE"
L24 0 SEA ABB=ON PLU=ON L22 AND TYROSINAMIDE
L25 1 SEA ABB=ON PLU=ON L22 AND LEUCINAMIDE
D SCAN
L26 0 SEA ABB=ON PLU=ON L22 AND NORVALIMIDE
E 676636-02-5/RN
L27 27 SEA ABB=ON PLU=ON (676636-02-5/RN OR 676636-03-6/RN OR 676636-04-7/RN OR 676636-05-8/RN OR 676636-06-9/RN OR 676636-07-0/RN OR 676636-08-1/RN OR 676636-09-2/RN OR 676636-10-5/RN OR 676636-11-6/RN OR 676636-12-7/RN OR 676636-13-8/RN OR 676636-14-9/RN OR 676636-15-0/RN OR 676636-16-1/RN OR 676636-17-2/RN OR 676636-18-3/RN OR 676636-19-4/RN OR 676636-20-7/RN OR 676636-21-8/RN OR 676636-22-9/RN OR 676636-23-0/RN OR 676636-24-1/RN OR 676636-25-2/RN OR 676636-26-3/RN OR 676636-27-4/RN OR 676636-28-5/RN)
L28 14 SEA ABB=ON PLU=ON L27 AND "L()VALINAMIDE"
E 676636-77-4/RN
L29 22 SEA ABB=ON PLU=ON (676636-77-4/RN OR 676636-78-5/RN OR 676636-79-6/RN OR 676636-80-9/RN OR 676636-81-0/RN OR 676636-82-1/RN OR 676636-83-2/RN OR 676636-84-3/RN OR 676636-85-4/RN OR 676636-86-5/RN OR 676636-87-6/RN OR 676636-88-7/RN OR 676636-89-8/RN OR 676636-90-1/RN OR 676636-91-2/RN OR 676636-92-3/RN OR 676636-93-4/RN OR 676636-94-5/RN OR 676636-95-6/RN OR 676636-96-7/RN OR 676636-97-8/RN OR 676636-98-9/RN)
L30 4 SEA ABB=ON PLU=ON L29 AND "L()VALINAMIDE"
E 676637-00-6/RN
L31 29 SEA ABB=ON PLU=ON (676637-00-6/RN OR 676637-01-7/RN OR 676637-02-8/RN OR 676637-03-9/RN OR 676637-04-0/RN OR 676637-05-1/RN OR 676637-06-2/RN OR 676637-07-3/RN OR 676637-08-4/RN OR 676637-09-5/RN OR 676637-10-8/RN OR 676637-11-9/RN OR 676637-12-0/RN OR 676637-13-1/RN OR 676637-14-2/RN OR 676637-15-3/RN OR 676637-16-4/RN OR 676637-17-5/RN OR 676637-18-6/RN OR 676637-19-7/RN OR 676637-20-0/RN OR 676637-21-1/RN OR 676637-22-2/RN OR 676637-23-3/RN OR 676637-24-4/RN OR 676637-25-5/RN OR 676637-26-6/RN OR 676637-27-7/RN OR 676637-28-8/RN)
L32 8 SEA ABB=ON PLU=ON L31 AND "L()VALINAMIDE"
E 676631-37-1/RN
L33 70 SEA ABB=ON PLU=ON (676631-37-1/RN OR 676631-38-2/RN OR 676631-39-3/RN OR 676631-40-6/RN OR 676631-41-7/RN OR 676631-42-8/RN OR 676631-43-9/RN OR 676631-44-0/RN OR 676631-45-1/RN OR 676631-46-2/RN OR 676631-47-3/RN OR 676631-48-4/RN OR 676631-49-5/RN OR 676631-50-8/RN OR 676631-51-9/RN OR 676631-52-0/RN OR 676631-53-1/RN OR 676631-54-2/RN OR 676631-55-3/RN OR 676631-56-4/RN OR 676631-57-5/RN OR 676631-58-6/RN OR 676631-59-7/RN OR 676631-60-0/RN OR 676631-61-1/RN OR 676631-62-2/RN OR 676631-63-3/RN OR 676631-64-4/RN OR 676631-65-5/RN OR 676631-66-6/RN OR 676631-67-7/RN OR 676631-68-8/RN OR 676631-69-9/RN OR 676631-70-2/RN OR 676631-71-3/RN OR 676631-72-4/RN OR 676631-73-5/RN OR 676631-74-6/RN OR 676631-75-7/RN OR 676631-76-8/RN OR 676631-77-9/RN OR 676631-78-0/RN OR 676631-79-1/RN OR 676631-80-4/RN OR 676631-81-5/RN OR 676631-82-6/RN OR 676631-83-7/RN OR 676631-84-8/RN OR 676631-85-9/RN OR 676631-86-0/RN OR 676631-87-1/RN OR 676631-88-2/RN OR 676631-89-3/RN OR 676631-90-6/RN OR 676631-91-7/RN OR 676631-92-8/RN OR 676631-93-9/RN OR 676631-94-0/RN OR 676631-95-1/RN OR 676631-96-2/RN OR 676631-97-3/RN OR 676631-98-4/RN OR 676631-99-5/RN OR 676632-00-1/RN OR 676632-01-2/RN OR

676632-02-3/RN OR 676632-03-4/RN OR 676632-04-5/RN OR 676632-05-6/RN OR 676632-06-7/RN)

L34 30 SEA ABB=ON PLU=ON L33 AND "L()VALINAMIDE"
E 676632-05-6/RN

L35 108 SEA ABB=ON PLU=ON (676632-05-6/RN OR 676632-06-7/RN OR 676632-07-8/RN OR 676632-08-9/RN OR 676632-09-0/RN OR 676632-10-3/RN OR 676632-11-4/RN OR 676632-12-5/RN OR 676632-13-6/RN OR 676632-14-7/RN OR 676632-15-8/RN OR 676632-16-9/RN OR 676632-17-0/RN OR 676632-18-1/RN OR 676632-19-2/RN OR 676632-20-5/RN OR 676632-21-6/RN OR 676632-22-7/RN OR 676632-23-8/RN OR 676632-24-9/RN OR 676632-25-0/RN OR 676632-26-1/RN OR 676632-27-2/RN OR 676632-28-3/RN OR 676632-29-4/RN OR 676632-30-7/RN OR 676632-31-8/RN OR 676632-32-9/RN OR 676632-33-0/RN OR 676632-34-1/RN OR 676632-35-2/RN OR 676632-36-3/RN OR 676632-37-4/RN OR 676632-38-5/RN OR 676632-39-6/RN OR 676632-40-9/RN OR 676632-41-0/RN OR 676632-42-1/RN OR 676632-43-2/RN OR 676632-44-3/RN OR 676632-45-4/RN OR 676632-46-5/RN OR 676632-47-6/RN OR 676632-48-7/RN OR 676632-49-8/RN OR 676632-50-1/RN OR 676632-51-2/RN OR 676632-52-3/RN OR 676632-53-4/RN OR 676632-54-5/RN OR 676632-55-6/RN OR 676632-56-7/RN OR 676632-57-8/RN OR 676632-58-9/RN OR 676632-59-0/RN OR 676632-60-3/RN OR 676632-61-4/RN OR 676632-62-5/RN OR 676632-63-6/RN OR 676632-64-7/RN OR 676632-65-8/RN OR 676632-66-9/RN OR 676632-67-0/RN OR 676632-68-1/RN OR 676632-69-2/RN OR 676632-70-5/RN OR 676632-71-6/RN OR 676632-72-7/RN OR 676632-73-8/RN OR 676632-74-9/RN OR 676632-75-0/RN OR 676632-76-1/RN OR 676632-77-2/RN OR 676632-78-3/RN OR 676632-79-4/RN OR 676632-80-7/RN OR 676632-81-8/RN OR 676632-82-9/RN OR 676632-83-0/RN OR 676632-84-1/RN OR 676632-85-2/RN OR 676632-86-3/RN OR 676632-87-4/RN OR 676632-88-5/RN OR 676632-89-6/RN OR 676632-90-9/RN OR 676632-91-0/RN OR 676632-92-1/RN OR 676632-93-2/RN OR 676632-94-3/RN OR 676632-95-4/RN OR 676632-96-5/RN OR 676632-97-6/RN OR 676632-98-7/RN OR 676632-99-8/RN OR 676633-00-4/RN OR 676633-01-5/RN OR 676633-02-6/RN OR 676633-03-7/RN OR 676633-04-8/RN OR 676633-05-9/RN OR 676633-06-0/RN OR 676633-07-1/RN OR 676633-08-2/RN OR 676633-09-3/RN OR 676633-10-6/RN OR 676633-11-7/RN OR 676633-12-8/RN)

L36 48 SEA ABB=ON PLU=ON L35 AND "L()VALINAMIDE"
L37 0 SEA ABB=ON PLU=ON (L34 OR L36) AND ALLOTHREONINAMIDE
L38 0 SEA ABB=ON PLU=ON (L34 OR L36) AND TYROSINAMIDE
L39 0 SEA ABB=ON PLU=ON (L34 OR L36) AND PHENYLALANIMIDE
L40 0 SEA ABB=ON PLU=ON (L34 OR L36) AND NORVALINAMIDE
L41 0 SEA ABB=ON PLU=ON (L34 OR L36) AND HEXENAMIDE
L42 0 SEA ABB=ON PLU=ON (L34 OR L36) AND PENTENOIC ACID
L43 0 SEA ABB=ON PLU=ON (L34 OR L36) AND HEXEN?
L44 0 SEA ABB=ON PLU=ON (L34 OR L36) AND LEUCINAMIDE

FILE 'STNGUIDE' ENTERED AT 08:27:22 ON 10 MAR 2009

FILE 'REGISTRY' ENTERED AT 08:28:18 ON 10 MAR 2009

L45 209 SEA ABB=ON PLU=ON L3 OR L5 OR L7 OR L10 OR L14 OR L16 OR L21 OR L23 OR L25 OR L28 OR L30 OR L32 OR L34 OR L36

FILE 'HCAPLUS' ENTERED AT 08:29:36 ON 10 MAR 2009

L46 11 SEA ABB=ON PLU=ON L45
E OVARIAN CANCER/CT
E E3+ALL

L47 24627 SEA ABB=ON PLU=ON "OVARY, NEOPLASM"/CT
L48 0 SEA ABB=ON PLU=ON L46 AND L47
L49 36120 SEA ABB=ON PLU=ON (OVAR?) (S) (CANCER? OR NEOPLAS? OR TUMOR? OR TUMOUR? OR CARCIN?)

```
L50             0 SEA ABB=ON  PLU=ON  L46 AND L49
L51             8 SEA ABB=ON  PLU=ON  L46 AND (CANCER? OR NEOPLAS? OR TUMOR? OR
                  TUMOUR? OR CARCIN?)
                  E NEOPLASM/CT
                  E E3+ALL
L52        203476 SEA ABB=ON  PLU=ON  NEOPLASM+OLD,UF/CT
L53             7 SEA ABB=ON  PLU=ON  L46 AND L52
                  E TUMORS/CT
                  E E3+ALL
L54        168148 SEA ABB=ON  PLU=ON  (TUMORS/CT OR NEOPLASM/CT)
L55             7 SEA ABB=ON  PLU=ON  L46 AND L54
L56             8 SEA ABB=ON  PLU=ON  L51 OR L55
                  SAVE TEMP L56 JEA722HCAP1/A

     FILE 'REGISTRY' ENTERED AT 08:37:10 ON 10 MAR 2009
                  SAVE TEMP L45 JEA722ALLCOM/A

     FILE 'STNGUIDE' ENTERED AT 08:37:31 ON 10 MAR 2009

     FILE 'REGISTRY' ENTERED AT 08:37:43 ON 10 MAR 2009

     FILE 'STNGUIDE' ENTERED AT 08:38:02 ON 10 MAR 2009

     FILE 'STNGUIDE' ENTERED AT 08:38:46 ON 10 MAR 2009
                  D QUE L45

     FILE 'REGISTRY' ENTERED AT 08:41:42 ON 10 MAR 2009

     FILE 'STNGUIDE' ENTERED AT 08:41:45 ON 10 MAR 2009

     FILE 'REGISTRY' ENTERED AT 08:41:54 ON 10 MAR 2009
                  D L45 1-209 IDE

     FILE 'STNGUIDE' ENTERED AT 08:42:13 ON 10 MAR 2009
                  D QUE L50
                  D QUE L56

     FILE 'HCAPLUS' ENTERED AT 08:42:57 ON 10 MAR 2009
                  D L56 1-8 IBIB ABS HITSTR HITIND

     FILE 'STNGUIDE' ENTERED AT 08:43:12 ON 10 MAR 2009
```